glutaraldehido 8

Critical Reviews in Toxicology, 22(3,4): 143-174 (1992)

A Critical Review of the Toxicology of Glutaraldehyde

Robert 0. Beauchamp, Jr., M.A., Mary Beth G. St. Clair, Ph.D.,*" Timothy R. Fennel/, Ph. D., David 0. Clarke, Ph. D., *** and Kevin T. Morgan, Ph.D. CIIT, P.O. Box 12137, Research Triangle Park, NC 27709

Frank W. Kari, Ph.D. NIEHS, Research Triangle Park, NC 27709

*To whom all correspondence should be addressed. **North Carolina State University, Raleigh, NC

***Eli Lilly and Company, Greenfield. IN

ABSTRACT: Glutaraldehyde, a low molecular weight aldehyde, has been investigated for toxicity in humans and animals. Examination of this dialdehyde was indicated from previous studies with other aldehydes in which carcinogenicity of formaldehyde and toxicity of acetaldehyde and malonaldehyde have been disclosed. Infor- mation gaps concerning the actions of glutaraldehyde have been identified in this review and recommendations are suggested for additional short- and long-term studies. In particular, information regarding irritation of the respiratory tract, potential neurotoxicity, and developmental effects would assist in a complete hazard evaluation of glutaraldehyde. Further study related to disposition, metabolism, and reactions of glutaraldehyde may elucidate the mechanism of action.

KEY WORDS: glutaraldehyde review, human toxicity, animal toxicity, reproductive toxicity, genotoxicity, metabolism, toxicokinetics, protein macromolecules, environment, health effects, aldehyde composition, uses.

I. INTRODUCTION

Glutaraldehyde is a specialty chemical with no single large-scale use. However, given its widespread use as a bactericide, a tanning agent, and a fixative, humans may be exposed to this chemical. This potential for human exposure, to- gether with the reactive nature of glutaraldehyde, has generated concern over possible adverse health effects associated with glutaraldehyde exposure. The activity of formaldehyde as a nasal carcinogen in rats and mice' and the toxicity of other low molecular weight aldehydes, such as acetaldehyde and malonaldehyde, have prompted further interest in this class of chemicals.2 Similar cellular mutation results reported for these aldehydes suggest carcinogenic potential.

This review represents a comprehensive survey of the toxicity of glutaraldehyde, its metabolism and disposition, reactions with macromolecules, in v i m and in vivo animal and human toxicity, genotoxicity and carcinogenicity, developmental toxicity, and environmental effects. Cited reference studies have been examined, and experimental design and results critically evaluated. The reference material has been summarized and evaluated to reveal information gaps for future investigations. Recommendations are proposed for consideration in such studies. While the primary focus of this review is on the toxicity of glutaraldehyde, additional information on the physical and chemical properties of glutaraldehyde, its production, uses, reactions, analysis, and regulation are also included.

1040-8444/92/$ .50 0 1992 by CRC Press, Inc.

143

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

II. PHYSICAL AND CHEMICAL PROPERTIES, AND PREPARATION

A. Physical Properties

Glutaraldehyde, a five-carbon dialdehyde, is a highly reactive compound that has been isolated as an oil and is usually stored as an aqueous solution. On storage, it forms mixtures containing hydrates, pyrans, and polymers. The principal physical properties of glutaraldehyde are summarized in Table 1 .

TABLE 1 Glutaraldehyde - Physical Properties

Structure - glutaraldehyde ( I )

OHC CHO I

B. Chemical Properties

Several studies have dealt with the determination of the composition of pure glutaraldehyde under a variety of circumstances. When chemical purity is a requirement, commercial solutions should be analyzed prior to use because the glutaraldehyde solution may not be limited to the monomeric form.

When considering the chemical nature of glutaraldehyde in solution, two types of studies have been conducted: those considering the equilib-

CAS Registry Number: 1 1 1-30-8

Molecular weight: 100.1 3

Physical state: Water-soluble oil

Freezing point: - 14°C

Boiling point: "C Pressure (mm)

187-1 88 (dec) 760 106-1 08 50 71 -72 10 60-61 1

0.0152 torr (50% aq. solution) at 20°C 0.0012 torr (2% aq. solution) at 20°C

Vapor pressure

Vapor density: 3.4 (air = 1)

Density: 0.72 (water = 1)

Refractive index: 1.43300(at 25°C; 589 nm)

Odor: pungent

Solubility: Soluble in all proportions in water and ethanol; soluble in benzene

Storage conditions: Stability of glutaraldehyde is decreased as the pH and

or ether

temperature are increased; pH effects were reported on two commercial solutions (containing 2% glutaraldehyde) revealing that a solution of Aldetex (pH 7.70) was more stable than a solution of Cidex (pH 8.55)

Ref.

233

14 15 14

234

66 66

235

233

236

13,237

66

238

1 44

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

rium forms in purified solutions, and those examining the forms, including polymers, present in commercially available preparations. The purity of glutaraldehyde solutions is frequently evaluated spectrophotometrically by measuring the ratio of absorbance at 235 and 280 nm to obtain a purification index. The absorbance at 280 nm corresponds to the n-n* transitions of the carbonyl bond of glutaraldehyde, whereas the absorbance at 235 nm corresponds to n-T* transitions of the C=C bonds of a,P-unsaturated polymers.

Generally, glutaraldehyde is stable to light, but is oxidized in air and polymerizes when heated. Studies have been directed toward elu- cidating the equilibrium conditions for glutaraldehyde under different conditions to indicate chemical modification of the parent structure and variation in its reactivity. The intermediate chemical forms are also considered in Section V1.C and D.

In a carefully monitored study, a 25% aqueous solution of glutaraldehyde was purified to a single peak with a UV absorbance maximum of 280 nm.3 The subsequent detection of a second peak at 235 nm indicated the formation of alternate forms, such as polymers, in investigations of the influence of pH, temperature, and buffering on polymerization rate. No polymerization occurred when a solution of glutaraldehyde was stored for 5 months at - 14°C. There was a slight increase in the 235 nm peak with storage at 4"C, and then a rapid increase in this peak beginning with storage around 20°C and continuing to 60°C. The polymerization rate of glutaraldehyde was increased when the pH was slightly acidic or basic; the rate of polymerization was decreased some- what by the addition of buffers. If a 50% degree of polymerization can be tolerated, samples may be stored at 4°C and pH 6.5 for up to 7 months.

A number of IH-NMR studies have been carried out on the nature of glutaraldehyde in aqueous solution and suggest the presence of the mono- hydrate, dihydrate, and cyclic hemia~etal .~ More recent studies have used I3C-NMR spectroscopy to examine the equilibrium in solution. In an extensively purified neutral solution of glutaraldehyde at 23"C, 4% free aldehyde (I), 16% he- mihydrate (11), 9% dihydrate (111), and 35% each of cis- and truns-isomers of the cyclic hemiacetal

(IV) were reported.' The equilibrium was found to be temperature dependent. In a further study,6 similar equilibrium proportions were observed, which were not greatly affected by pH or concentration. The isolation and identification of polymers of glutaraldehyde (V) from aqueous solution have been the subject of several investigations (Figure 1). Oligomers have been isolated and characterized from aqueous solutions of glutaraldehyde. 'J The para-glutaraldehyde (VI) , a trimer, is the principal trioxane derivative, with the pentamer (VII) and heptamer (VIII) present in small amounts (Figure 2). The polymerization of glutaraldehyde is pH-dependent , with increasing polymerization at higher pH. Isolation of the various derivatives was performed by HPLC, with characterization by IR and NMR spectroscopy. Commercial 25% glutaraldehyde solutions may contain precipitates that result from aldol condensation.' This condensate contains aldehyde groups conjugated with ethylenic double bonds and may react with amino groups in amino acids to yield imino groups. The ethylenic bond and the imino bond are stabilized by resonance, and this stable form will not allow Michael-type addition reactions.

n n OHC CH(OHk (HOLCH CH(OHh

n OHC CHO

I II 111

IV V

FIGURE 1. Equilibrium structures of glutaraldehyde in aqueous solution.

Other types of polymers reported to be in a 2% alkaline glutaraldehyde sterilizing solution (pH 7.5 to 8.5) were trioxane oligomers (oligomers of VI) of molecular weights > 12,000. l o The characterization of a dimer (IXa) from an aqueous alkaline solution of glutaraldehyde has been reported recently (Figure 3). I ' This dimer is formed by a dimolecular aldol condensation, and may exist in equilibrium with the cyclic hemiacetal form (IXb).

1 45

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

VI (Tdrner) VII (Pentamer)

R R R

Vlll (Heptemer)

FIGURE 2. Oligomers of glutaraldehyde in aqueous scluticn. R :epresen!s (CH,),C!-!O.

oHcQCHO O H C a OH

1x0 IXb

FIGURE 3. Dimers of glutaraldehyde.

C. Preparation

Recent production figures for glutaraldehyde are not available. The principal manufacturer in the U.S. is Union Carbide Corporation; non- domestic producers include BASF AG in Europe and Daicel Chemical Industries, Ltd. in Japan. In 1976, an approximate production volume of >5000 lbs. was listed. I 2 . I 3 Production figures have not been reported in the published literature.

Isolation and characterization of glutaraldehyde from the ozonolysis of cyclopentene were first reported by Harries and Tank. l 4 More recent methods utilize alkoxy-pyran derivatives as the source of the 5-carbon chain of glutaraldehyde.

The principal method of commercial production of glutaraldehyde (I) is the acid hydro- lysis of a 2-alkoxy-3,4-dihydro-2H-pyran (X) (Figure 4). I

H20, HOAC n OHC CHO

I ocy Reflw, 1 hour

X

FIGURE 4. Principal commercial preparation of glutaraldehyde from 2-methoxy-3,4-dihydro-2H-pyran (X).

111. USES

Major uses of glutaraldehyde depend on its highly reactive chemical properties where reaction may occur with proteins or polyhydroxy compounds to modify the surface characteristics or internal properties of the treated substrate. Tanning of animal skins with glutaraldehyde is a prime example involving reaction with proteins as well as preparing tissues by various fixative processes for microscopic study. This strong reactivity of glutaraldehyde also exhibits a broad spectrum of biocidal activity. Many disinfectant and sterilizing procedures require special bactericidal, slimicidal, sporicidal, fungicidal, or vi- rucidal activity. I6s1' Other principal applications of glutaraldehyde include the treatment of various skin disorders, an adhesive in dentistry, and a component in the manufacture of tissue transplants.

The tanning of leather with glutaraldehyde produces leather of outstanding durability, uni- formity, and feel and improves the properties of lining, sole, gloving, horsehide, and pigskin. Water-resistance or insolubilization is imparted to cork in the manufacture of gaskets and wash- able wallpaper. Increased water-resistance and wet strength have been extended for treated paper towels when rapid wetting without tearing is required. Textile sizing mixtures prepared from polyhydroxy materials such as polyvinylacetate and polyvinyl alcohol and followed by addition of glutaraldehyde at elevated temperatures yielded effective materials for use under high-humidity conditions.

The preservative or antimicrobial effect of glutaraldehyde has found broad application in cosmetic, toiletry, and chemical specialty product^'^ due to its ready water solubility and usefulness in systems containing secondary

146

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

amines, tertiary amines, quaternary ammonium compounds, or protonated amines. The broad biocidal activity is due to the cross-linking capacity of the difunctional aldehyde with primary amines, such as lysine residues present in the microbial cell

The antimicrobial activity of glutaraldehyde is suitable for numerous hospital settings requiring a readily available, noncaustic liquid sterilant usable under ambient conditions for surgical and examination instruments. Glutaraldehyde is an effective sporicidal agent requiring about 3 h for almost complete elimination of spores. Gram- positive and Gram-negative bacteria, fungi, and viruses are also susceptible to the lethal action of glutaraldehyde.21 Care should be exercised to remove or minimize any residual aldehyde to prevent sensitization reactions for the operator or patient.

Glutaraldehyde has been used in the development of vaccines against a variety of allergens including Bordella pertussis, ragweed, and grass pollen^.^^-^^ Using glutaraldehyde-fixed simian immunodeficiency virus (S1V)-infected cells, a vaccine was produced that protected macaques from SIV infection; all eight monkeys vaccinated with the glutaraldehyde-modified antigen were protected from a challenge with active SIV.25

Glutaraldehyde is available in several different commercial preparations, providing the user with a choice for a particular application. Two preservative formulations containing glutaraldehyde are sold under the trade names of Ucaricide Preservative 225 and Ucaricide Preservative 250.19 The Ucaricide 225 contains 25% by weight glutaraldehyde and the Ucaricide 250, 50% by weight glutaraldehyde with pH ranges from 3.1 to 4.5. Other glutaraldehyde products include additional Ucaricides, and tradename products - Piror, Uconex, Ucarsan, and Aqucar - all containing glutaraldehyde and available for special uses.26 These preservatives are recommended for use in controlling bacterial growth in cosmetics, toiletries, oil field operations, pigment and filler slurries, metal working fluids, farm equipment, and housing. Preservatives are also recommended as water treatment in cooling towers and filtering systems, and chemical specialty prod-

ucts. Inactivation of glutaraldehyde may occur in the presence of ammonia and primary amines.

In an early report, the stability and bactericidal effectiveness of a buffered formulation of glutaraldehyde were increased from 14 to 28 days after activation. The activation process is carried out by mixing the individual ingredients of the separate formulations. A 2% glutaraldehyde solution containing a surfactant to promote wetting plus sodium nitrite as a corrosion inhibitor and buffered to a pH of 7.5-8.0 was stable for up to 28 days. 27 An unformulated alkaline glutaraldehyde solution retained its bactericidal activity for only 14 days.28 An additional important property of the stable formulation is its ability to retain bactericidal activity in the presence of organic matter. Recent information on the storage stability of several Ucaricides disclosed that no change was observed in the concentration of glutaraldehyde for up to 52 weeks at 25 and 37"C.26

Glutaraldehyde is used in various clinical applications involving skin treatment ,29 dentistry30 and tissue implants, as well as in the manufacture of contact lenses and preservation of blood products. Skin problems that are effectively treated include the removal of warts and excessive sweating of the hands and feet. The common wart, verruca vulgaris, is treated effectively with a 10% glutaraldehyde ~olut ion.~ ' A 25% solution was also effective, but a buffered 10% solution with sodium bicarbonate to pH 7.5 was pre- ferred. Other skin disorders treated successfully with glutaraldehyde are epidermolysis bullosa, herpes simplex, herpes zoster, and pitted kera- t o l y s i ~ . ~ ~ - ~ ~ While contact dermatitis from the use of high concentrations of glutaraldehyde on the soles of the feet is rare, exposure of other regions of the body to more dilute concentrations of glutaraldehyde caused sensi t izat i~n.~~ These observations have been interpreted in terms of extensive binding of glutaraldehyde to the keratin of the skin of the soles of the feet and the relative paucity of Langerhans cells in this area.39

A palmar antiperspirant formulation containing 5% glutaraldehyde was recommended over a 10% solution to minimize tanning during the sweat reduction process. The nonalkalinized solution is applied three times per week.34 Excessive sweat-

147

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

ing of the feet (hyperhydrosis) was treated with a 10% buffered solution of glutaraldehyde and the sweating was relieved within 24 h.37

Glutaraldehyde is used in the preparation of grafts and bioprostheses, often from nonhuman tissues, that are to be transplanted into humans. Glutaraldehyde treatment of xenografts stabilizes and preserves them, and glutaraldehyde-treated graft materials elicit fewer allergic reactions than formaldeh yde-fixed materials ,40 presumably due to decreased tissue antigeni~ity.~'*~* Problems associated with glutaraldehyde-treated xenografts most commonly are due to calcification or me- chanical failure of the graft.4347 Co-treatment of graft materials with glutaraldehyde and aminopropanehydroxydiphosphonate or chon- droitin sulfate may reduce destructive graft cal-

cross-link collagen in applications for surgical implant materia148*50-52 and has been used for linking materials intended to improve biocom- patibility to synthetic graft^.^^.^^ Tissue degradation and humoral antibody induction are reduced by this treatment. Artificial pretreated polyester vessels and valves are rendered antithrombogenic by final cross-linking with glutaraldehyde.53 An improved collagen implant cross- linked with glutaraldehyde, Zyplast, gives longer- lasting corrections in improving acne scars than without the cross-linking process.5o Immuno- genic responses to Dacron prostheses are reduced when the device is coated with albumin or collagen and then cross-linked with glutaralde- h ~ d e . ~ ~ Glutaraldehyde-treated grafts appear to be important in human medicine, but efforts should continue toward improving glutaraldehyde fixation of these tissues in order to obtain satisfactory fixation while maintaining a low potential for rejection and calcification.

Soft contact lenses, prosthetics, films, and fibers were prepared from gelatin and cross-linked with glutaraldehyde. Flexible, clear, and dimen- sionally stable products were obtained by this procedure. 56

Glutaraldehyde has been used to stabilize hemoglobin in the preservation of blood products requiring a long shelf life. The life of glutaraldehyde-treated red blood cells is extended, but further improvements are needed to prevent rig- idity, antigenicity, and reduced o~ygen-affi i ty.~~

CiiEICaiioii.4R 49 G~~txald&liyde is albu used b

Fixation of tissue specimens using glutaraldehyde when preservation of the ultrastructure for study by electron microscopy and cytochemistry was required has been in use since the early 1960~.'~ Glutaraldehyde was reporteds9 to be pre- ferred over formaldehyde because the fine structure is stabilized and gross distortion during embedding is prevented. It was also found to cause the least protein conformational changes. Some caution has been indicated in its use in cytochemistry by an early report showing evidence of activation of a nucleic acid phosphatase enzyme with glutaraldehyde.@' In some applications, glutaraldehyde followed by osmium tetroxide was more effective than osmium tetroxide alone in revealing granular vesicles in the pineal body. However, it has one drawback in that it is rlui capabie of rendering iipids insoiubie in organic solvents and thus will not allow demon- stration of cellular membranes. Glutaraldehyde penetrates tissues much less than formaldehyde, probably due to its greater reactivity, and slightly less than osmium tetroxide.

IV. ADVERSE HEALTH EFFECTS IN HUMANS

Humans can be exposed to glutaraldehyde in numerous clinical and occupational settings, as indicated by the many different uses of this chemical. A majority of the adverse health effects reported for glutaraldehyde are associated with dis- infection or sterilization procedures performed by hospital personnel or its use in a variety of clinical settings. Clinical exposures result from its use in removal of skin warts, dental adhesives, the sterilization of health care equipment, and the manufacture of tissue implants and prosthetic devices.

Glutaraldehyde has been used successfully in the treatment of a number of skin disorders, including epidermolysis bullosa, hyperhydrosis, herpes zoster, herpes simplex, dyshidrosis, on- ychomycosis, and warts. Undesirable effects of these treatments have ranged from skin discol- ration,^^-^^,^^ to contact dermatitiP and ulceration.62 A patient was exposed to residual glutaraldehyde via a crack in an anesthesia mask,

1 48

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

which resulted in eye i r r i t a t i ~ n . ~ ~ An accidental subdural injection of glutaraldehyde proved to be fatal."

Recently, potential occupational hazards to personnel and patients exposed to either formaldehyde or glutaraldehyde in hospital operating and patient rooms have been reported in Ger- m a n ~ . ~ ~ When cleaning solutions containing 0.038% formaldehyde or 0.025% glutaraldehyde were used in these settings, the maximum allowable airborne concentrations were not exceeded, i.e., 0.5 ppm formaldehyde or 0.2 ppm for glutaraldehyde. However, when cleaning solutions were formulated with either 0.228% formaldehyde or 0.15% glutaraldehyde, unacceptable airborne concentrations resulted. Exposure concentrations of 5.1 ppm formaldehyde and 0.57 ppm glutaraldehyde were detected; acceptable short- term levels are 1.0 ppm for formaldehyde and 0.4 ppm for glutaraldehyde.

Human exposure to low concentrations (< 1 ppm; odor threshold is 0.04 ppm of glutaraldehyde) either by inhalation or skin contact may cause irritation of the skin and/or mucous membranes.% Contact dermatitis, eye irritation, and/ or skin discoloration are frequently observed from such occupational exposure^.^^-^^ Elevated concentrations of glutaraldehyde and extended pe- nods of human exposures may cause respiratory distress and secondary infections resulting from severe irritation and ulceration of exposed sites. Rhinitis and encrustation of mucous membranes have also been reported. 83

Glutaraldehyde is a moderate sensitizer of human kin,^^.^^.^^.^^ but was scored as a nonir- ritant in the in v i m cultured corneal endothelial cell assay. 88 Because of the frequent combined use of glutaraldehyde and formaldehyde (e.g., in the disinfectant Cidex [CAS #37245-61-71), as well as the frequent use of these two compounds in the same workplace settings (e.g., funeral homes, histology laboratories), the issue of cross- sensitization between the two compounds has been investigated. 37*89*90 No evidence of sensitization to glutaraldehyde resulting from formaldehyde exposure, or vice versa, was found. Skin sensitization has been reported from exposure to glutaraldehyde-tanned leatheP and to a hair conditioner containing glutaraldehyde as a preservative .91

Glutaraldehyde is employed in human dentistry to prevent spread of disease in decayed teeth both by its antibacterial and cross-linking activities30 and was found to have a number of advantages over formocresol in this capacity.92-94 In addition, an aqueous solution of glutaraldehyde and 2-hydroxymethacrylate sold under the tradename GLUMA (Bayer) has been used as a bonding agent between the restorative resin and the dentin of the t o ~ t h . ~ ~ . ~ ~ The bond was formed by reaction with the amino groups of collagen initially and then with the methacry late ester. Pretreatment with EDTA (ethylenedi- aminetetraacetic acid) is needed to free the collagen from the imbedding apatite. This adhesive is markedly cytotoxic to cultured human buccal epithelial cells. In vivo studies revealed that cheek pouches of non-human primates exposed to GLUMA bond exhibited extensive necrosis and ~lceration;~' however, this formulation markedly decreased the incidence of bacterial infections in filled teeth, compared to another bonding agent.98 Minor irritation has been reported in humans whose root canal sites were prepared with glutaraldehyde-containing bonding agents .94 Glutaral- dehyde was shown to decrease dentin demineralization, potentially acting to prevent tooth decay.w In contrast to formocresol, glutaraldehyde is not extensively absorbed from pulpotomy sites, loo thus limiting systemic exposure. Comparative studies of the toxicity of glutaraldehyde and formaldehyde on penapical tissues suggest that glutaraldehyde is useful and safe when applied to pulpotomy sites, as long as prolonged contact with surrounding tissues does not occur. '01-'03

The cytotoxicity of residual glutaraldehyde in xenografted tissues prepared for transplantation into humans has been the subject of several investigations. Sufficient residual glutaraldehyde to cause cell death in various cell lines was found in a number of graft material^.^'*^@'-^^^

In 1980, NIOSH published a National Hazard Survey citing 35,083 occupational exposures to glutaraldehyde for the period 1972-1974. lo' This number represents about twice the number of exposures for either benzaldehyde or furfural, and five times that for acrolein (NCR Committee on Aldehydes, 198 l ) , indicating that glutaraldehyde exposure represents a substantial proportion of human exposure to aldehydes in industry.

149

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

Based on the foregoing information, indicating that exposure to glutaraldehyde may cause respiratory tract or dermal irritation, and coupled with data indicating the potential for glutaraldehyde to induce DNA damageIw as well as cell proliferation, l l 0 human exposure to glutaraldehyde must be minimized by the use of protective clothing, respirators, and adequate ventilation. In addition to the irritating effects of glutaraldehyde, sensitization has been reported. Clini- cians should be aware of this possibility when using glutaraldehyde to treat skin disorders. Tis- sue implants and prostheses prepared with glutaraldehyde should be tested carefully to ascertain the absence of residual available glutaraldehyde prior to transplantation.

Precaution in the use of glutaraldehyde as a tissue fixative is indicated in the guidelines for histotechnology and electron microscopy. Its similarity to formaldehyde has been noted and represents a potential skin and eye irritant. 1 1 1 - 1 1 3

V. GOVERNMENT REGULATIONS

OSHA published a final rule for the ceiling concentration (PEL - permissible exposure limit) on glutaraldehyde of 0.8 mg/m3 (0.2 ppm) based on irritant effects to the eyes, nose, and throat associated with short-term exposures. I l 4 Ceiling concentration is a peak not to be exceeded at any time during the working day. Previously, OSHA had no limit for glutaraldehyde, but had proposed establishing the limit at 0.2 ppm based on the recommendation of ACGIH published in 1986.66 NIOSH concurred with this proposed limit and the final rule in 1989 established this limit. No values have been published for the 8-h time- weighted average or short-term limit (duration for 15 min, unless otherwise noted) for glutaraldehyde.

The threshold recognition level for glutaraldehyde has been reported to be 0.04 ppm by volume in air." However, eye and respiratory tract irritation was not noted until the concentration reached 0.3 ppm, or about seven times the odor threshold.66

The environmental consequences of glutaraldehyde have been considered in the Soviet

Union in two settings, and restrictions were reported. The recommended maximum threshold concentrations of glutaraldehyde in large water reservoirs is 0.07 mg/1.'15 In the case of circu- lating vapors and aerosols in factory environments, a maximum allowable concentration for glutaraldehyde has been set at 5 mg/m3, or six times the present concentration allowable in the U.S.

Reuse of glutaraldehyde-containing disinfectant solutions and other dialysis supplies is being considered as part of the Health Care Financing Administration (HCFA) Medicare program. An airborne exposure ceiling of 0.2 pprn glutaraldehyde was established in this application in ac- cordance with the previous OSHA limit.

The food additive regulation was amended by FDA to allow use of glutaraldehyde as a slim- icide in the manufacture of paper and paperboard that may come in contact with food."*

A proposed rule was published by the MSHA (Mine Safety and Health Administration) in which a Hazard Communications Chemical List was included for chemicals that may be present or shipped to a mine site.119 The rule proposes that employees and employers must be provided with information concerning potential hazard for such chemicals as glutaraldehyde that may be utilized in mining processes. Processes may include flo- tation procedures involving natural products that contain a variety of chemicals. The final rule is not expected until 1993.

In reviewing the literature, no risk assessments or exposure standards for glutaraldehyde, other than the OSHA PEL and ACGIH Threshold Limit Value, were identified.

VI. METABOLISM, PHARMACOKINETICS, AND REACTIVITY

A. Absorption and Disposition

The uptake of glutaraldehyde has been investigated in a variety of biological systems typ- ical of the potential routes of exposure associated with glutaraldehyde use. These include absorption through skin and from the pulp chamber of

150

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

teeth. Dermal absorption studies conducted in vitro using human stratum corneum from the chest, abdomen and sole, and epidermis from the abdomen, demonstrated that glutaraldehyde does not penetrate the thick stratum corneum of the sole.12o However, 3.3 to 13.8% of the applied dose penetrated the thin stratum corneum of chest and abdomen, and 2.8 to 4.4% of the applied dose penetrated the isolated epidermis. In a more recent study of the in vitro penetration of glutaraldehyde in samples of skin from F-344 rats, CD-I mice, rabbits, guinea pigs, and humans, < 1 % of the applied glutaraldehyde penetrated the skin.

Material balance studies have been camed out in vivo in both male and female F-344 rats, and in New Zealand white rabbits.Iz2 [1,5- ''C]Glutaraldehyde was administered intrave- nously (0.2 ml for rats and 2.5 ml for rabbits of either 0.075 or 0.75% solutions) and dermally (0.2 ml of 0.075, or 7.5% solutions in rats, and 2.5 ml of 0.75 or 7.5% solutions in rabbits). Following intravenous administration in both rats and rabbits, the majority of the radioactivity was excreted as I4CO2, with approximately 80% being exhaled in the first 4 h. Urinary excretion of radioactivity was considerably lower, ranging from 8 to 12% in the rat, and 15 to 28% in the rabbit. At the higher dose, excretion of I4CO, as a percentage of total dose was less than at the lower dose, particularly in the rabbit, where urinary excretion and tissue retention were increased. Following dermal administration, the majority of the administered radioactivity was recovered at the application site in the rat, with only approximately 5% of the applied dose being absorbed. This contrasts with findings in the rabbit, in which between 32 to 53% of the dermal dose was absorbed and either excreted or found in tissues. Pharmacokinetic investigations were also carried out in both the rat and rabbit using intravenous and dermal routes of administration. lZ2 Pharmacokinetic analyses were performed on the levels of radioactivity in plasma. The dermal absorption rate constants were low, ranging from 0.2 to 2.0 h-' in both species. The long terminal half-lives calculated for glutaraldehyde may result from a combination of binding to protein and slow excretion of its metabolites.

Absorption studies of glutaraldehyde following its use as a fixative in human root canal preparations have been carried out. On imgation of the root canals of human teeth with an unspecified amount and concentration of 14C-glutaraldehyde, radioactivity remained localized in the canal and its borders, with no detectable diffusion into the surrounding tooth structure.'O' Glutar- aldehyde absorption was investigated in vital pulpotomy sites in the canine and incisor teeth of mongrel dogs.Io3 A cotton pellet containing 5.6 pCi of [1,5-'4C]glutaraldehyde as a 2.5% solution was inserted into each of 16 pulpotomies per animal. After 5 min, the pellets were removed, and blood, urine, and expired air were collected for 90 min. Tissues were removed for assay of radioactivity. Approximately 3% of the total applied dose was absorbed systemically. Urinary excretion accounted for 8% of the absorbed dose, and pulmonary excretion about 4%. Tissue-to- plasma ratios for I4C indicated that binding probably occurred in red blood cells (2.21), and to a lesser extent in other tissues.

B. Metabolism

Extensive metabolism of glutaraldehyde to expired CO, has been described in a number of in vivo studies following dermal, intravenous, and pulpal e x p o ~ u r e ' ~ ~ * ~ ~ ~ in which [ 1,5- ''C]glutaraldehyde was used as tracer. Excretion of urinary metabolites of glutaraldehyde has been r e p ~ r t e d , ' ~ ~ . ' ~ ~ but none of the metabolites have been characterized.

Glutaraldehyde is oxidized by rat liver mitochondria in vitro, as measured by an increase in oxygen consumption.123 The oxidation is under the control of the electron transport system, and results in reduction of NAD+ and consumption of two atoms of oxygen per molecule of glutaraldehyde. Glutaraldehyde is oxidized extensively to CO, in rat tissue slices, with the highest activity in the kidney, followed by the liver.'25 The activity is localized in the mitochondria1 fraction of the kidney.

The ability of a number of enzyme systems to metabolize glutaraldehyde has been investigated. For the isoenzymes I, IIa, and IIb of human liver aldehyde dehydrogenase (aldehyde:

151

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

NAD + oxidoreductase, EC 1 .2.1.3), glutaraldehyde was a poor substrate compared with other aliphatic aldehydes. While isoenzyme I had a low activity for oxidation of glutaraldehyde compared with acetaldehyde, isoenzymes IIa and IIb had similar K, and V,,, values for these two aldehydes. Glutaraldehyde was reported to be a poor substrate for an aldehyde dehydrogenase isolated from liver microsomes of rats treated with clofibrate, which had previously been shown to increase the specific activity of the enzyme.”’ Glutaraldehyde was also a poor substrate for two isoforms of cytosolic aldehyde dehydrogenases isolated from rat liver.Iz8 An enzyme that had been considered as an isoenzyme (E4, ALDH IV) of human liver aldehyde dehydrogenase (EC 1.2.1.3), now identified as glutamic-y-semialdehyde dehydrogenase or 1 -pyrroline-5-carboxy- late dehydrogenase (EC 1.5.1.12), had a high capacity for metabolism of glutaric semialdehyde, which would be produced on oxidation of glutaraldehyde. The NAD + -dependent succinic semialdehyde dehydrogenase (EC 1.2.1.24), isolated from human brain mitochondria was ca- pable of using glutaric semialdehyde as a substrate for oxidation, but at a lower rate than succinic semialdehyde. I3O

The metabolism of glutaraldehyde has been followed with [ 1 ,5-’4C]glutaraldehyde, and while it has been determined that the majority of radioactivity is transformed both in vivo and in vitro to 14C02,103~122~123~125 the fate of the unlabeled carbon atoms has not been directly established. Al- though direct identification of metabolites has not been carried out, it is probable that glutaraldehyde undergoes oxidation to glutaric semialdehyde, and then to glutaric acid. A postulated metabolism scheme for glutaraldehyde is outlined in Figure 5. This acid can undergo further metabolism by synthesis of a coenzyme A thioester, either by a thiokinase reaction or by transfer of CoA from succinyl CoA catalyzed by a thio- phorase.”’ The glutaryl CoA produced then undergoes reduction by glutaryl CoA dehydrogenase (EC 1.3.99.7) to give glutaconyl CoA and decarboxylation to crotonyl CoA.I3I Glutaryl CoA is normally produced from a-ketoadipyl CoA, formed during the catabolism of tryptophan, lysine, and hydroxyly~ine.~~~ A deficiency of glutaryl CoA dehydrogenase is the primary defect

OCHCyC H.$ YCHO

NADH NAD+ 2 OC HC Y C Y C Y C OOH

NADH NAD+ 2 HOOCCyCH&H&OOH

J HOOC C I+C OSCoA

FADY

HOOCCI+CH-CH:OSCoA

h ‘I - c q

C H& K C H: OSC OA

J C H& HOH: Y C OSC oA

I I + t

C H& OSC oA I I I

CQ

FIGURE 5. Postulated metabolism scheme for glutaraldehyde. (1) Oxida- tion of glutaraldehyde to glutaric y-semialdehyde and (2) further oxidation to glutaric acid; (3) synthesis of glutaryl Coenzyme A; (4) oxidation to glutaconyl CoA; (5) decarboxylation to give cro- tony1 CoA; (6) hydration to p-hydroxybutyryl CoA; (7) conversion to acetyl CoA; (8) oxidation to CO,.

associated with the inherited human metabolic disorder, glutaric aciduria type I, which is characterized by highly elevated glutaric acid in the urine.’33 Enoyl CoA hydratase (EC 4.2.1.55) can then convert this compound to P-hydroxybutyryl CoA, which can subsequently be used for synthesis of acetoacetate, or be degraded to acetate and then to CO,. Further metabolic studies on glutaraldehyde should consider this overall se-

152

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

quence in the isolation and characterization of urinary metabolites.

The principal metabolism of glutaraldehyde to CO,, and the potential for the metabolite incorporation into macromolecules, complicates the assessment of the fate of glutaraldehyde in vivo. While the deposition of radioactivity at the site of administration may be due to binding to macromolecules, it currently cannot be distinguished from the metabolic incorporation of radiolabel into the normal monomers required for synthesis of macromolecules. Thus, an understanding of the products formed on reaction of glutaraldehyde with macromolecules is essential to the measurement of covalently bound glutaraldehyde.

C. Reaction with Proteins

Many of the uses (tanning agent, tissue fixative, biocide) of glutaraldehyde are related to its ability to react with and cross-link proteins. '34 Glutaraldehyde can react with the a-amino groups of amino acids, the N-terminal amino groups of peptides, and the sulfhydryl group of cysteine. 135

The predominant site of reaction in proteins was at the €-amino groups of lysine, with some reaction also with tyrosine, histidine, and sulfhy- dry1 residues. The reaction with proteins is rapid and pH dependent, with the rate increasing at alkaline pH. 136 Glutaraldehyde-treated proteins develop a yellow color, and undergo an increase in UV absorbance between 250 and 300 nm, with a blue shift in absorbance maximum of about 5 nm. Gels or precipitates are formed on treatment of some proteins with glutaraldehyde.

The mechanism of reaction of glutaraldehyde with protein has been the subject of debate. Al- though it has been suggested that unsaturated polymers formed by aldol condensation of glutaraldehyde are responsible for the reaction with p r ~ t e i n , ~ . ' ~ ' the reaction of proteins with purified and unpurified glutaraldehyde are almost iden- tical, suggesting that the initial presence of polymers is not required.*O

The mechanisms of reaction of glutaraldehyde with amino acids are outlined in Figure 6. It is generally assumed that glutaraldehyde initially reacts with amino acids to form Schiff bases with reactive amino groups.'38 The reaction of amino acids with glutaraldehyde has been inves-

tigated using lysine and 6-aminohexanoic acid as a model system.139 Reactions were carried out at room temperature in an aqueous unbuffered solution. The products were purified and characterized as polymeric 1,3,4,5-tetrasubstituted pyridinium salts (XXI). These could be formed by the initial reaction of three molecules of glutaraldehyde with one of lysine. Further reaction with a lysine side chain and two additional molecules of glutaraldehyde could lead to the formation of a cross-link.

On treatment of ovalbumin with glutaraldehyde in an aqueous solution at pH 4.5 and isolation of the reaction products from the hydro- lyzed protein, several products were identified. 1 -(5-Amino-5-carboxypentyl)pyridinium chloride (XIX) was formed by reaction of a single molecule of glutaraldehyde with lysine to give a cyclic dihydropyridine derivative, which could then undergo oxidation to the pyridinium derivative. The isolation of 1 -(5-amino-3-carboxypen- ty1)-3- [ 1 -(5- amino-5-carboxypentyl)-2-piperi- dyllpyridinium chloride (anabilysine, XXII), formed by reaction of two molecules of glutaraldehyde with two lysine residues, was also described. Glutaraldehyde reaction with primary amines is known to consume oxygen, which is thought to be involved in the oxidation of dihydropyridine derivatives to pyridinium compounds. 1 4 '

it was suggested that, following initial reaction of glutaraldehyde with amines to form Schiff bases, further reaction with glutaraldehyde forms a conjugated Schiff base, which then reacts with additional lysine molecules, either by Michael addition or by reaction at the free aldehyde groups.

The complexity of the reaction products, the ability of glutaraldehyde to polymerize, and the difficulty associated with examining the cross- linking process have made this a difficult area of study. The elucidation of the mechanism of the cross-linking process will require further investigation.

In an earlier

D. Reaction with DNA

Little information is available on the reaction of glutaraldehyde with DNA or the components of DNA. Products were formed on reaction of

153

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

H I

R-N D C H O -

t

J Q I

R

XVl l

XXI I R XIX

FIGURE 6. Possible reactions of glutaraldehyde with the €-amino groups of peptide-bound lysyl residues. R-NH, represents a peptide-bound lysine residue, Glut the carbon backbone of glutaraldehyde, and n = 1-40. XI is a Schiff base formed on reaction between the amine and glutaraldehyde. XI1 is a Schiff base formed by reaction with an a$-unsaturated dimer." Xll l is a subsequent Michael addition product. XIV represents a cross-link formed by generation of a Schiff base. XV and XVI are Schiff bases formed by reaction of amines with glutaraldehyde polymers. XVll and XVlll represent the dihydropyridine and dihydropyridinium compounds described by Hardy et al.,140 and XIX and XX the pyridinium derivatives formed on o~ ida t ion . '~~~ '~ ' XXI and XXll (anabilysine) are cross-linked products proposed by Hardy et a1.139p140 (Adapted from Reference 142.)

glutaraldehyde with deoxyadenosine, deoxyguanosine, and deoxycytidine, but not with de- oxythymidine. 143 The adducts formed with deoxyadenosine were unstable, but those formed on reaction with deoxyguanosine were relatively stable. Based on the reactivity of glutaraldehyde with various substituted guanosine derivatives, the UV and fluorescence spectra of the adducts, and the retention of radiolabel on reaction with [8-3H]guanosine, the position of substitution is most probably the exocyclic amine group.

The reaction of DNA or RNA with glutaraldehyde, as measured by increasing absorbance at 260 nm, occurs only at elevated temperatures (>6OoC), at which the nucleic acids undergo melting. 14'No evidence for intermolecular DNA- DNA cross-linking was observed. DNA-protein cross-linking was detected by alkaline elution in replicating human TK6 lymphoblasts treated with sublethal concentrations of glutaraldehyde. 145 The reaction of glutaraldehyde in biological systems to form DNA adducts or DNA-protein cross-links

154

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

could have considerable consequences and is an area that requires additional investigation.

VII. TOXICITY STUDIES

The studies described in this review have focused mainly on glutaraldehyde preparations that also contain oligomers and polymers. No studies have addressed the potential toxic effects of the oligomers and polymers alone, or in combination with monomeric glutaraldehyde.

A. In Vivo Studies

Many studies designed to assess the toxicity of glutaraldehyde have limited relevance to the principal routes of human exposure in the workplace, where inhalation and dermal exposures are by far the most common. Several toxicity studies rely on drinking water as the route of exposure,’22 which may relate to only a limited number of food products. A more appropriate assessment of human risk resulting from exposure to glutaraldehyde would be possible with systematic examination of the respiratory tract following long- term inhalation exposure to low levels of this compound, or examination of skin lesions following repeated dermal exposure. In this section, findings of studies to assess the in vivo toxicity of glutaraldehyde are examined. A detailed list of acute (LD50, LC,J studies is followed by a summary of glutaraldehyde toxicity resulting from exposure by various routes (e.g., intravenous, oral, dermal, ocular, and inhalation).

The acute toxicity of glutaraldehyde, either alone or diluted with water or corn oil, has been investigated in a variety of species. The results are reported in Table 2.

Following a single oral administration of aqueous solutions of glutaraldehyde (0.5 to 50% w/w), signs of toxicity in rats included piloerec- tion, red periocular and perinasal encrustation, sluggish movement, rapid breathing, and diar- rhea. Survivors showed no gross pathological lesions at necropsy, whereas the animals that died displayed distension of the stomach with congestion and hemorrhagic areas in the stomach wall,

congestion and distension of the small intestine, and variable congestion of the adrenals, kidneys, liver, spleen, and lungs. 122 Glutaraldehyde caused no morphologically identifiable lesions in a 3- month study in which rats received 0.5, 2.5, or 5% glutaraldehyde in the diet. This study was performed to affirm the Generally Recognized As Safe (GRAS) status of glutaraldehyde, which is used in the food industry to cross-link edible collagen sausage casings. 146 Following 11 weeks of administration of 0.25% glutaraldehyde in drinking water, rats exhibited no evidence of damage in the peripheral or central nervous systems. 14’ These studies were conducted because of glutaraldehyde’s structural similarity to the neurotoxicant 2,Shexanedione. However, no data are available that indicate neurotoxic effects of glutaraldehyde. The results of a 13-week subchronic study with dogs exposed to glutaraldehyde by drinking water were expected to be published in an updated review during 1991.26

Glutaraldehyde is presently classified as a primary dermal irritant, and dermal application to the skin of rabbits caused moderate irritation.26 Several reports have linked glutaraldehyde exposure to irritation and/or allergic-type responses. Glutaraldehyde proved to be strongly positive in the mouse ear sensitization assay. 14* Severe local inflammation and punctate necrosis were observed following an occluded patch test on rabbit skin using 25% glutaraldehyde. The concentration threshold for glutaraldehyde-induced erythema was judged to be 1%.’49

Contact hypersensitivity has been reported in mice and guinea pigs resulting from dermal application for 5 to 14 days of 0.3 to 3.3% glutaraldehyde. I5O Other investigators have demonstrated the induction of a weak immunologic response in rabbit^.^^,'^^ Glutaraldehyde also caused a 90% inhibition of graft-vs.-host reactions in mice. 152 Glutaraldehyde administered subcutaneously to male rats for 35 days at 25 or 125 mg/kg/day caused an increased number of white blood cells, decreased levels of hemoglobin and lymphocytes, hypertrophy of white pulp in the thymus, atrophy of the thymus, and degeneration of renal tubules. Urine and blood chemistries were essentially in the normal range except for elevated serum urea nitrogen and urine total protein levels. 153

155

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

TABLE 2 Acute Toxicity of Glutaraldehyde (LD,dLC,)

Species

Rat

Rat

Rat

Rat

Rat

Rat

Rat

Rat

Rat Rat Rat Mouse Mouse

Mouse (male)

Mouse (male)

Mouse Mouse Rabbit

Rabbit

Rabbit

Rabbit

(male)

(female)

Route

Inhalation

Inhalation

Inhalation

Oral

Oral

Oral

Oral

Oral

S.C.

i.p. i.v. Oral Oral

Oral

S.C.

i.p. i.v. Oral

Oral

Oral

Skin

LD,value

5000 ppm (LC50) 24 PPm (LC50) 40 PPm (Lc50) 1.30 ml/kg 50% aq. soh. (wlw)

1.87 ml/kg 25% aq. soh. (wlw)

3.3 ml/kg 5% aq. soln. (w/w)

12.3 ml/kg 1% aq. soln. (w/w)

96.1 mglkg 2% Cidex formultn.

2390 mglkg 17900 pglkg 15300 pg/kg 100 rng/kg 1300 mglkg 25% olive oil soln.

122 mg/kg 2% Cidex formultn.

1430 mg/kg

13900 pg/kg 15400 pg/kg 1.59 ml/kg 50% aq. s o h (w/w)

8.0 ml/kg 25% aq. soh. (w/w)

> 16 ml/kg 5% aq. soh. (w/w)

2560 pglkg

Solutions of glutaraldehyde (instilled as a single application and observed for 14 days) were markedly irritating to the eye, causing conjunc- tivitis at concentrations >0.1% and corneal injury at concentrations <0.5%.21,149 In contrast, glutaraldehyde was scored as a noninitant in the in vitro cultured human corneal endothelial cell assay; this test in intended for use as a replacement for the in vivo Draize test used to determine eye-irritating potential. 89

Observations from a number of single exposure and short-term repeated exposure inhalation studies in which rodents were exposed to glutaraldehyde in the parts per million range re-

Comment Ref.

4-h period 239

4-h period 122

4-h period 122

122

122

122

122

153

153 239 239 239 240

153

153

239 239 122

122

122

239

vealed that these exposure levels were associated with significant respiratory distress, as is subsequently discussed. A single 24-h inhalation exposure of NMRI mice to either 33 or 133 mg/l of glutaraldehyde vapor resulted in nervous be- havior, excessive washing and panting, accom- panied by toxic hepatitis in six of ten mice in the high dose group.'54 A single 8-h inhalation exposure of rats to saturated glutaraldehyde vapors resulted in signs of toxicity and irritation including excess lacrimation and salivation, audible breathing, and mouth breathing, but no deaths during a 14-day follow-up period.IZ2 Single inhalation exposures of rats to statically generated

156

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

glutaraldehyde vapors (with chamber concentrations decreasing from 11 to 2 ppm over a 6-h period) caused sensory and respiratory tract irritation. 149 Inhalation exposure of rats to glutaraldehyde (0 to 3.1 ppm, 6 Wday, 9 days) resulted in significant mortality at the high concentration, depressed body weight gain, signs of sensory irritation, and inflammation of the nasal mucosa at 3.1 and 2.1 ppm.’49 The acute toxicity of glutaraldehyde was studied in CD/CrlBr rats by in- stilling into one nostril 40 pl of aqueous solutions ranging from 20 to 40 mM.’5s.1s6 This procedure resulted in minimal response, despite clear concentration-related toxic histopathological changes in the nose. Nasal lesions induced by a single instillation of glutaraldehyde included inflammation, epithelial degeneration, respiratory epithelial hypertrophy, and squamous metaplasia. These lesions were associated with local increases in cell replication and were considered by the to closely resemble lesions induced in the nasal passages of rodents by acute inhalation exposures to a number of irritant gases, including glutaraldehyde. It was proposed that direct application of the test article to the surface of interest (nasal epithelium) made this technique useful for studies of upper airway toxicity. How- ever, the authors stated that this is a “non-phys- iologic” approach,’56 and care should therefore be taken when interpreting nasal instillation studies for risk assessments of inhaled materials.

The effects of long-term inhalation exposure to glutaraldehyde have not been thoroughly examined. A 90-day inhalation study in mice and rats (exposure concentrations 0 to 1000 ppb) sponsored by National Toxicology Program (NTP) was completed recently. Preliminary published results reveal that glutaraldehyde caused nasal epithelial lesions with increased cell proliferation (measured by tritiated thymidine incorporation) in the anterior nasal cavity at 1000 ppb, with less severe lesions at 500 ppb and minimal to no changes at concentrations of 250 ppb and below. The glutaraldehyde-induced nasal lesions were not considered to be preneoplastic in nature. Is6

The glutaraldehyde-induced lesions occurred more anteriorly in the nose of the rat than those reported for formaldehyde. 1 5 7 3 1 5 8 Both neoplastic and non-neoplastic formaldehyde-induced nasal lesions occur principally in the lateral meatus and

on the mid-ventral nasal septum. Following inhalation exposure of rats and mice to concentrations of glutaraldehyde of 250 to 1000 ppb, there was damage to the squamous epithelium of the nasal vestibule and to the respiratory epithelium closely adjacent to this region.lS9 Both the distribution and the morphological characteristics of the lesions induced by glutaraldehyde differed from those of formaldehyde. Furthermore, the preneoplastic changes reported for formaldehyde following a 90-day exposure to 10 or 15 ppm formaldehydelm were not observed with glutaraldehyde. 159 An earlier subchronic inhalation study revealed that daily exposure to 0 to 194 ppb of glutaraldehyde resulted in perinasal wet- ness and significantly decreased body weight gain at 49 and 194 ppb. No evidence of damage to the nasal mucosa was found in this study, and despite elevated serum enzymes (phosphokinase, lactate dehydrogenase, hydroxybutyric dehydrogenase), no histopathological lesions were found in any organ system.161 Comparison of chronic/ neoplastic responses to glutaraldehyde with those of formaldehyde and other aldehydes awaits com- pletion of a chronic inhalation study of glutaraldehyde at concentrations of 250 ppb or above.

Cardiotoxic effects of simple aliphatic aldehydes including glutaraldehyde and related compounds were investigated in dogs following a single intravenous exposure (1 to 10 mg/kg). Glutaraldehyde and formaldehyde caused prolonged Q-T periods, resulting in ventricular fi- brillation but no significant sympathomimetic effect. 16* Structure activity relationships indicated that the aldehyde group caused the Q-T prolon- gation, but an adjacent free methyl or hydroxyl group to the aldehyde group eliminates the effect.

Residual Cidex (a commercial disinfectant formulation containing 2% glutaraldehyde) on instruments used for arthroscopic surgery has been suspected as the cause of postsurgical compli- cations. Synovial irritation occurred when rabbit joints were injected with 0.5 ml of various di- lutions of Cidex, beginning at 10 ppm (0.1 kg glutaraldehyde). The degree of synovial inflammation was directly proportional to the concentration of Cidex to which the joint was exposed. These studies demonstrated the need for careful rinsing of instruments following Cidex disinfec- tion to avoid chemical irritation of joints. 163 This

157

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

response was judged to be a chemical rather than an allergic response.

In vivo studies strongly suggest the potential for adverse effects at the site of application resulting from dermal, ocular, or inhalation exposure to glutaraldehyde. However, the likeli- hood of systemic toxicity following in vivo exposure would appear to be slight, given the extreme reactivity of glutaraldehyde and its tend- ency for limited distribution from the site of ap- plicatiodexposure. Io1 -lo3

B./n Vitro Studies

The effects of glutaraldehyde solutions and vapor on the viability and dividing ability of nu- iliei-oiis lilies of cultured cells have been investigated. A number of these studies were of limited value because cells were treated with elevated concentrations of glutaraldehyde in the range used for tissue fixation (1.25 to 2.5 M, corresponding to 2 to 4% glutaraldehyde). Other in v i m data were reported from studies investigating the potential use of glutaraldehyde in novel clinical applications.

High concentrations of glutaraldehyde (0.58 to 10 M) were toxic to cultured L cells;164 these cells were found to be more sensitive to formaldehyde than to glutaraldehyde, with decreased growth, but no loss of viability observed at 160 d formaldehyde and 400 mM glutaraldehyde.I6’ Glutaraldehyde (25 mM) was found to be extremely cytotoxic to cultured HeLa cells. Millimolar concentrations of glutaraldehyde inhibited mitosis in eggs of Triturus helveticus Raz., acting on kinetochores in a manner similar to quinoline, but unlike antitubulin agents such as colchicine, vinblastine, or podophyllotoxin. 167.168 Glutaraldehyde also decreased proliferation of HL60 leukemia cells, with the appearance of numerous polyploid cells at a glutaraldehyde concentration of 100 mM. 169 Glutaraldehyde vapor inhibited the propagation of unspecified lines of cultured cells.17o Exposure of human TK6 lymphoblasts to 10, 15, and 20 @I4 glutaraldehyde in serum-free media for 30 min resulted in the death of 10, 50, and 90% of the cells, respectively. 109-145*171 Primary hepatocyte cultures tolerated 100 JLM glutaraldehyde for 18 h with minimal damage. l w

A number of investigations demonstrated that glutaraldehyde can kill or reduce the malignancy of a number of tumor cell lines. Glutaraldehyde was used in mechanistic studies of foreign-body tumor induction171 and in studies of density-dependent growth inhibition. 172 Dilute solutions of glutaraldehyde have been shown to be effective in killing Ehrlich carcinoma cells in mice and for the prevention of recurrent tumors at anastomotic suture lines following surgical resection of colon cancers. 173 Glutaraldehyde treatment reduced the malignancy of 4C 1 cells. 174 Glutaraldehyde- treated malignant cells were shown to be more susceptible to antibody-dependent, macrophage- mediated cytolysis than nonglutaraldehyde-treated tumor cells, and glutaraldehyde-treated malignant cells have been successfully used to produce tumor immunopropnyiaxis in mice against a variety of tumor line^.'^^-'^^

Glutaraldehyde was compared to a series of alkylating agents and other aldehydes for immunosuppressive activity . Glu taraldehyde (50 mM) was more effective in lymphocyte deacti- vation in vitro than chloroacetaldehyde, which is a metabolite of the immunosuppressive drug cyclophosphamide. 152

Numerous reports on the effects of glutaraldehyde modification on red blood cells and hemoglobin (Hb) have resulted from efforts to improve the shelf life of blood products using glutaraldehyde as a preservative. Glutaraldehyde concentrations up to 50 mM had no effect on the density, mean cell volume, or potassium-retain- ing ability of red blood cells.57 Glutaraldehyde- modified Hb reversibly bound oxygen. l8O.I8l However, Hb extensively modified by glutaraldehyde did not contribute to oxygen transport in artificial red blood cells. Glutaraldehyde has been shown to either or i n c r e a ~ e ] ~ ~ . ~ ~ ~ the affinity of Hb for oxygen. Glutaraldehyde decreased the osmotic fragility and deformability of red blood cell^,'^^^^^ presumably due to sta- bilization of cytoskeletal and surface proteins. Glutaraldehyde altered the surface charge and electrophoretic mobility of red blood cells186 and decreased catecholamine-stimulated CAMP formation. 187

Several reports disclose the use of glutaraldehyde-modified proteins to enhance drug delivery to target tissues. Microcapsules comprised of glutaraldehyde-cross-linked proteins, intended for

158

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

the delivery of anticancer drugs to tumors, caused reversible inhibition of proliferation of cultured cells (e.g., human erythroleukemic cell line K562) at the G2 phase of the cell cycle.’88 In addition, glutaraldehyde treatment of erythrocytes loaded with adriamycin provided an efficacious dosing regimen in B6C3F1 mice.Is9 This modified drug formulation, which was found to be less cardiotoxic, was excreted at a slower rate and remained at the site of action (lung or liver tumor) for longer periods of time. A moderate increase in plasma transaminase and alkaline phosphatase activities was observed after injection of the modified drug form, but histopathology revealed no hepatocellular injury.

Potential neurotoxic effects of glutaraldehyde were investigated by observing the changes in excitability and conduction in the frog sciatic n e r ~ e . ’ ~ ~ . ’ ~ ’ Immersion of the nerve in a Ringer solution containing glutaraldehyde revealed irreversibly decreased amplitude of nerve action potential, causing a complete action potential block, purportedly due to inactivation of sodium and potassium ion channels. A 1% solution of glutaraldehyde was found to be an effective inhibitor of adenosine uptake in rat brain synaptosomes, 192 while lower concentrations of glutaraldehyde specifically inhibited the temperature- induced allosteric modification of high-affinity [3H]tryptamine-binding sites. 193

C. Genotoxicity of Glutaraldehyde

Short-term genotoxicity tests with glutaraldehyde have yielded inconsistent responses, ranging from no activity to unequivocal mutagenicity. The variability stems primarily from the choice of biological test system. Early reviews of the genotoxicity of glutaraldehyde suggested that the compound was nonmutagenic, 194,195 but recently more sensitive assays investigating specific genomic lesions have yielded positive results.

Glutaraldehyde was found to be negative in the Escherichia coli WP2 uvrA reversion assay (without activation) when tested at six concentrations ranging from 20 to 10,000 & . I g 6 These same investigators also found glutaraldehyde to be unreactive in uitro using 4-(p-nitrobenzyl)- pyridine or deoxyguanosine as the alkylation tar-

gets. Glutaraldehyde also proved to be nonmutagenic in the SOS-chromotest using E. coli F‘Q37 as the tester strain. 19’ Results of the genotoxicity tests in the NTP ranged from no activitylg8 to weakly positive activity (causing an approximate doubling of background mutants) in Salmonella reversion assays when tested in strains TA100, TA1535, TA1537, and TA98 at doses ranging from 33 to 3333 pg/plate.199 The greatest activity was observed in strain TAlOO at doses ranging from 10 to 200 pg/plate. Convincing mutagenicity data were reported from tests employing Salmonella strains TA102 and TA104,200-202 which were developed for increased sensitivity toward carbonyl compounds. In the absence of activation, glutaraldehyde (25 pg/plate) caused a 2.5-fold increase in mutation frequency above background in TA 102. Using a semiquantitative approach, glutaraldehyde was found to be one of the most active mutagenic carbonyl-containing compounds, with 100 pg/plate causing a 13-fold increase in reversion frequency without activation in TA104.201 Glutaraldehyde was also found to be mutagenic, independent of S9 activation, in the umu test. 203 Glutaraldehyde-induced DNA damage was also indicated by positive results in the liquid r e c - a s ~ a y . ~ ~ ~ ~ * ~

In other genotoxicity assays, glutaraldehyde (8 pg/ml) was a potent mutagen in the mouse lymphoma cell line.2o5 Likewise, glutaraldehyde treatment (10 to 20 cl.M> caused an approximately sevenfold increase in the trifluorothymidine-re- sistant mutant fraction in cultured human TK6 lymphoblasts. 145 Glutaraldehyde was negative in the Drosophila sex-linked recessive lethal test.206 Oral doses of glutaraldehyde (30 to 60 mg/kg) were negative in the mouse dominant lethal assay.*07 Glutaraldehyde (2.5%) caused damage (irreversible swelling) of chromosomes isolated from cultured Chinese hamster B14 and Don C cells in vitro.z08 Mixed results were obtained in cytogenetic evaluations of glutaraldehyde. In one report, glutaraldehyde (1 1 to 15 pg/ml) did not induce sister chromatid exchange (SCE) in Chinese hamster ovary cells,2o9 while another laboratory reported these same doses to be positive with or without activation.210

Evaluation of glutaraldehyde-induced unscheduled DNA synthesis (UDS) in the male rat liver following oral administration of the com-

159

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

pound revealed that glutaraldehyde did not induce DNA damage repaired by an excision process.2" However, because of the ability of glutaraldehyde to react rapidly and irreversibly with proteins, it is unlikely that any unreacted glutaraldehyde actually reached the liver under this treatment regimen. Assessment of glutaraldehyde-induced UDS in primary hepatocyte cultures treated with 0 to 100 @I4 glutaraldehyde revealed a modest dose-related response, with only the highest dose exhibiting a statistically significant increase over controls. 145

In order to affirm the GRAS status of glutaraldehyde used in sausage production, glutaraldehyde-treated edible sausage casings were subjected to short-term genotoxicity testing. The casings did not prove to be mutagenic in either an Aliies test (usiag liri unq~e~ i l i zd sirain of Sal- monella) or in the mouse lymphoma cell

In conclusion, glutaraldehyde exhibits mutagenic activity, and the majority of the positive studies suggest that glutaraldehyde induces oxidative damage to DNA in cells exposed to the compound. Glutaraldehyde is also markedly cytotoxic. This combination of adverse effects raises concern about the safety of individuals to repeated exposure to glutaraldehyde via the skin and/or respiratory tract.

D. Carcinogenicity

Currently, there are no adequate long-term bioassay studies on the potential carcinogenicity of glutaraldehyde reported in the published literature. Glutaraldehyde has been nominated for evaluation of chronic toxicity and carcinogenicity by NTP.

E. Developmental Toxicity

Only a few studies have reported the potential embryotoxicity of glutaraldehyde, even though it is used as a disinfectant in hospitals and as a fixative in laboratories, where a high level of female employment exists. Although most of the cited literature does not provide data on occupational exposure levels, the cumulative available information from human epidemiological

studies as well as laboratory animal investigations indicates a low hazard for developmental toxicity from glutaraldehyde exposure.

Perhaps the most valuable data have been obtained from retrospective epidemiological studies that assessed the incidences of spontaneous abortions and fetal malformations in Fin- nish hospital nurses and instrument sterilizing staff who had been exposed to sterilizing agents (glutaraldehyde, formaldehyde, and ethylene oxide) and/or cytostatic drugs, anesthetics, and X-irra- d i a t i ~ n . ~ ~ ~ . ~ ' ~ These studies suggested an increased frequency of spontaneous abortions with exposure to ethylene oxide, as well as an asso- ciation between maternal use of cytostatic drugs and fetal malformations in offspring of staff involved in such sterilization procedures .214 How- ever, there was no significant increase in risk of either endpoint in staff performing sterilization or nurses exposed to glutaraldehyde or formal- d e h ~ d e . ~ ~ ~ . ~ ' ~ In the 1982 the reported increase in the crude rate of spontaneous abortions correlated with exposure to glutaraldehyde before adjusting for age, parity, decade of pregnancy, smoking, and alcohol and coffee consumption. The authors indicated that, while it is less potent than ethylene oxide, glutaraldehyde may not be absolutely safe.214 No information on birth defects was reported in these studies.

Investigations in experimental animals also indicated a low occurrence of developmental toxicity as a result of glutaraldehyde exposure during pregnancy. A study conducted by Mar- vishi Pharmaceutical Company found no embryotoxic effects in the offspring of mice treated by gavage with up to 30 mg/kg of glutaraldehyde on days 7 through 12 of gestation.'22 Sonacide (acidified glutaraldehyde containing 2% glutaraldehyde w/v; Ayerst Laboratories, Inc., New York, NY) was embryotoxic following oral administration to CD- 1 mice during days 6 to 15 of gestation. Although highly toxic to pregnant dams at concentrations above 2.0 ml/kg/day (40 mg glutaraldehyde/kg/day), Sonacide only affected fetuses at the highest dose of 5 ml/kg/day, which also killed more than half of the dams.21s At this dose, the average fetal weight was significantly reduced and 1 1.7% of the fetuses were malformed. Similarly, oral doses of 25 and 50 mg/kg of glutaraldehyde given to albino rats on

160

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

days 6 to 15 of pregnancy were maternally toxic but were not fetotoxic.Iz2 Preliminary results of a prenatal toxicity study in which rabbits were given glutaraldehyde by gavage ( 5 , 15, and 40 mg/kg/day for 13 consecutive days) have recently been reported.216 The high dose was severely maternally toxic and caused a significant increase in implantation loss and reduction of the mean body weight of surviving fetuses. The two lower doses were apparently nontoxic to either the dam or embryo/fetus.

While rodent studies have not assessed the developmental effects of inhalation exposure to glutaraldehyde, indirect evidence suggests that significant systemic absorption and distribution would not occur, probably due to high chemical reactivity and metabolism . O 1 9 lo3, I 22

Using a mouse embryo culture system, qual- ity-control analyses of media preparations for human in vitro fertilization programs have provided information on the effects of glutaraldehyde on preimplantation embryo development. Extreme toxicity to cultured mouse embryos was observed when the culture medium was passed, prior to use, through an oocyte aspiration needle that had been sterilized with either Cidex or Cidex-7, formulations that contain 2% glutaraldehyde each. Cidex-7 also contains ingredients to mask the odor of glutaraldehyde and has a shelf life of 28 days, in contrast to 14 days for Thorough washing of instruments with 1.5 to 3 .O I of sterile water reversed the embryotoxicity of Cidex-sterilized instruments, but had no effect on toxicity caused by sterilization with Cidex- 7.220 These findings suggest that the method of instrument sterilization could be a contributing factor to unsuccessful in vitro fertilization at- tempts in humans. Studies of potential early embryo losses following in vivo glutaraldehyde administration to laboratory animals during the preimplantation period are currently lacking.

In summary, maternal exposure in occupational settings does not appear to contribute to spontaneous abortions or fetal malformations. On the other hand, studies in laboratory animals have demonstrated adverse effects of glutaraldehyde on the developing embryo and fetus. Direct contact with preimplantation embryos in vitro was shown to be embryolethal, and postimplantation exposure to glutaraldehyde was developmentally

toxic in mice and rabbits. However, because glutaraldehyde exposures that induced embryo/fetotoxicity in animals in vivo also caused severe maternal toxicity, it is difficult to delineate the cause of the embryo/fetotoxicity. Based on these studies, glutaraldehyde should be regarded as a potential developmental toxicant, but effective doses may be above those that elicit toxicity in the adult, i.e., having low developmental hazard.2z' Further studies are necessary to more fully characterize these effects and the associated human risk.

F. Reproductive Toxicity of Glutaraldehyde

There is currently little published information that specifically addresses the potential reproductive toxicity of glutaraldehyde.

No studies were found that investigated glutaraldehyde effects on female reproductive function and fertility. Dosing during the organogen- esis period of pregnancy, however, revealed no adverse effects on embryonic development except at high doses that were also severely maternally toxic.

One study examined the effects of glutaraldehyde on male reproductive function using the dominant lethal assay.2o7 Male mice were administered a single oral dose of 30 or 60 mg/kg glutaraldehyde and mated for the next 6 weeks with virgin females. There was no evidence of reduced fertility in treated males and no statistically significant effects on embryo/fetal viability were recorded.

VIII. ENVIRONMENTAL EFFECTS

The antimicrobial properties of glutaraldehyde have been applied in many hospitals where cold sterilization was required. 78 This application represents an occupational hazard to the hospital staff, causing irritation and sensitization to eyes, skin, and respiratory tract. It has been suggested that precautions be taken by keeping the aldehyde atmospheric concentration below 0.2 ppm, wear- ing protective gloves and gowns, providing fa- cilities for decontamination of eyes and skin, and

161

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

testing for sensitivity to asthma or allergic dermatitis. Sterilization of several polymeric materials in the hospital environment was performed and residues of glutaraldehyde were detected on catheters and feeding tubes. Io5 The concentration of the aldehyde in these materials increased with time of contact. Rinsing with heparin in a sodium chloride solution was not effective for removing the aldehyde residues.

The effect of glutaraldehyde in water was analyzed with respect to taste, smell, and antimicrobial action on saprophytic microflora in large water reservoirs. The organoleptic (taste and smell) properties of water were reported to be unaffected by glutaraldehyde at a maximum concentration of 100 mg/l. Saprophytic microflora are not affected at a concentration up to 0.1 mg/i. i 5

Bifunctional organic compounds, such as glutaraldehyde, contribute to the formation of suspended particulate matter and to aerosol components in the atmosphere.z22 Some products es- caping into the atmosphere are derived from pho- tochemical degradation of cyclic alkenes to form derivatives such as glutaraldehyde by reaction with ozone and hydroxyl radicals.

A simple procedure was devised to determine the relative toxicity of effluents containing aldehyde contaminants from purification plants. z23

The method is based on the BOD (biological oxygen demand) of an ordinary effluent sample and a chemically contaminated effluent sample in which the microorganisms present in each effluent are allowed to consume oxygen. The test is focused on the consumption of oxygen by the microorganisms (unspecified species) not inhibited by toxic agents. Thus, a sample having a high oxygen demand would be ranked less toxic than one with a low oxygen demand. Of four aldehydes examined, the glutaraldehyde sample consumed the least amount of oxygen, closely followed by formaldehyde. Propionaldehyde was the least toxic, followed by acetaldehyde. These results indicate a need for caution in discharging effluent containing glutaraldehyde.

IX. RECOMMENDATIONS

1. In future studies designed to assess toxic effects of glutaraldehyde, the test material

2.

3.

4.

5 .

should be characterized as to composition because of the ready spontaneous formation of polymers. An essential component of the assessment of risk posed by exposure to glutaraldehyde is the evaluation of hazard. Evaluation of the effects of long-term exposure on the respiratory tract and the potential neurotoxic, developmental, and behavioral effects of glutaraldehyde would provide a more complete hazard evaluation. An important factor in the disposition and metabolism of glutaraldehyde is its extensive reactivity with macromolecules, with much of the administered material remain- ing at the site of application. The effect of exposure by routes such as inhalation requires investigation and may assist in elucidation of the mechanism of action. The products formed on cross-linking of glutaraldehyde with proteins and nucleic acids should be investigated. These could serve as biomarkers and provide additional insight into the toxicological action of glutaraldehyde. Data provided from these foregoing recommended studies should be incorporated into a risk assessment for glutaraldehyde.

APPENDIX A - CHEMICAL REACTIONS

Glutaraldehyde is very reactive chemical due to the presence of two aldehydic groups. Glu- taraldehyde undergoes the usual reactions associated with aliphatic aldehydes, but in many reactions both terminal aldehyde groups may be involved yielding various cyclic derivatives. This review lists representative reactions of the bifunctional aldehyde that may have some rela- tionship to biological systems and environmental conditions.

The principal types of reactions between glutaraldehyde and other chemical species have been classified into three categories. Illustrative reaction sequences are outlined in Table 3 for each of these classes. Several reactions have been re- viewed by Evanszz4 and original cited references should be examined for description of the experimental conditions used by earlier workers.

162

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

TABLE 3 Glutaraldehyde Reactions

1. Glutaraldehyde (G) and active hydrogen compounds Water-hydrated forms of GZ4’

OHC n W O W 2 (H0)zCH n CH(OH)2 Ho QOH H O O O L IV V II 111

Alcohols [ROH; glycols; pentaerythritol yields polymers]

RO n

(RO)&H CH(OR)2

Ethylene glyc01~25 ch (CH2)3 9 Amines {aliphatic or aromatic amines (RNH,))242

RNH2 + I 4 0- Piperidines

O - N ~ Mp 49-5O’C Benzene

Reflux 24 % yield

6 + I - Primary amine (RNH,) + RCOOH (Mannich-type condensation)

Hydrazines {H,N-NHR; H,N-NRR’}

H =NH l r H R CH =NH-NR2

Nucleic aid^^^^,^^

G+ adenosine I + R N h 4 RN=CH(CH&CH-NR cytidine guanosine or (or equivalent deoxyri bonucleoside)

Nofe: Schiff base products revert to original compounds

Amino acidsT4,

unless reduced to form amines.

NH2 I

4 Schm Bases I + R-CH-COOH Subttttuted plperidiner Polymers

163

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

TABLE 3 (continued) Glutaraldehyde Reactions

Thi~phenols”~

RSH + I L RS O S R + RS\ OSR

RS sH(CH 2 h C e SR

Thioglycolic acida4

HSCH2COOH + I 4 S

CH2tCHCOCH3 + I - CH~COCHZCH~CO \ P I 3

CHaCOCH&H&O

3. Reduction reactions (see also Schiff bases

“O\

G-bishemiacetal

From the illustrative reactions of glutaraldehyde in which cyclic tetrahydropyran or piperidine derivatives are formed, consideration should be given to the formation of cis and trans isomers with the asymmetric carbon atoms in the heterocyclic rings. These two isomeric forms of cyclic tetrahydropyrans are illustrated in Figure 7. The potential biological activity of one isomer in contrast to the other, or even a mixture of the two, should be considered in product applications.

APPENDIX B - ANALYSES

A procedure was published recently for the analysis of glutaraldehyde in the a s z s using gas chromatography in which concentrations of 0.03 to 2 ppm of the aldehyde can be determined. An oxazolidine derivative is formed from the reaction of glutaraldehyde and 2-hydroxymethylpip-

L HOCH,(CH&CH2OH

1 ,bpentanediol

H-. f i H H n O H

HO 0 OH HO 0 H

IVa IVb

FIGURE 7. Cis and trans isomers of the tetrahydropyran form of IV glutaraldehyde.

eridine, which yields two peaks (UV) due to the presence of diastereoisomers .(Figure 8).

An alternate rapid test for the presence of low concentrations (1 to 2 mg/l) of aldehydes such as glutaraldehyde is the addition of a reagent containing a p-rosaniline compound, a phosphate compound (sodium monobasic orthophosphate) ,

164

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

FIGURE 8. Reaction of glutaraldehyde with 2-hy- droxymethyl-piperidine to form an oxazolidine derivative.

and water.226 This test is effective for determining glutaraldehyde in rinse solutions on medical equipment.

Glutaraldehyde concentrations have been measured in workplace atmospheres containing several contaminants by means of an HLPC method.227 This method can be adapted to both particulates and vapors. The aldehydes are de- rivatized to form 2,4-dinitrophenylhydrazones, which are ideally suited for HPLC analysis and also absorb strongly in the UV range. A similar procedure was used for the analysis of a mixture of aldehydes (glutaraldehyde, formaldehyde, and acrolein), converting them to the corresponding hydrazones prior to UV analyses.22* Limits of detection of these aldehydes in an air sample by means of a UV spectrophotometer were estimated as follows: glutaraldehyde, 0.02 mg/m3; formaldehyde, 0.04 mg/m3; and acrolein, 0.015 mg/ m3. A recent report using a similar procedure for separate detection of formaldehyde and glutaraldehyde disclosed limits of 0.05 ml/m3 and 0.02 mum3, respectively, in 5-1

The dinitrophenylhydrazone derivative of glutaraldehyde has also been utilized in the OSHA Analytical Laboratory229 for detecting the aldehyde in an air sample at a concentration of 4.4 ppb (or 18 pg/m3). The sample was analyzed by means of HPLC using a UV detector.

A novel photoreduction-fluorescence (PRF) method that detected aldehydes, alcohols, or ethers involves the reduction of anthraquinone in the absence of oxygen.23o The resultant highly fluorescent hydroquinone allowed detection limit of 31 ng of glutaraldehyde.

An index of purification has been proposed by comparing the UV spectra of both commercial and vacuum-distilled glutaraldehyde samples.23' The impure material exhibited a higher extinction at 280 nm than the purified product at 235 nm, while the reverse was seen with distilled aldehyde. The index of purification (I,) was stated to be valid only if the temperature and concen-

trations of glutaraldehyde were known at the time of sample measurements: I, = E235/E280.

Prior analyses of commercial glutaraldehyde substantiated the pure aldehyde peak at 280 nm and also the importance of storage at low temperatures ( <2OoC) for extended periods.232 The rate of deterioration in an inert atmosphere, such as in nitrogen, was slightly less than a glutaraldehyde sample over an 8-month storage period at low temperature (<O°C) in air.

ACKNOWLEDGMENTS

The authors wish to convey their grateful appreciation to the reviewers who contributed much in focusing on the principal issues and potential concerns for glutaraldehyde. The reviewers included Drs. Gregory Kedderis, Frank Welsch, Julian Preston, Russell Cattley , Rajen- dra Chhabra, and Dan Morgan. Special acknowl- edgement is expressed for the support and en- couragement from Chemical Industry Institute of Toxicology, The Procter & Gamble Company, and National Institute of Environmental Health Sciences in the preparation of this publication as an adjunct in the study of aldehydes.

The Information Services staff at CIIT has assisted greatly at all stages in the production of this manuscript and personal thanks are extended to Linda Smith, Willanna Griffin, Beth William- son, and Rita Berman.

REFERENCES

1 . Swenberg, J. A., Kerns, W. D., Mitchell, R. E., Gralla, E. J., and Pavkov, K. L., Induction of squamous cell carcinomas of the rat nasal cavity by inhalation exposure to formaldehyde vapors, Cancer Res., 40, 3398, 1980.

2. National Institute of Occupational Safety and Health, Carcinogenicity of acetaldehyde and malonaldehyde, and mutagenicity of related low-molecular-weight aldehydes, Current Intelligence Bulletin 55, NIOSH Publ. No. 91-112, September 1991.

3. Rasmussen, K.-E. and Albrechtsen, J., Glutaral- dehyde. The influence of pH, temperature, and buffering on the polymerization rate, Hisrochemistry, 38, 19, 1974.

165

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

4. Hardy, P. M., Nicholls, A. C., and Rydon, H. N., Nature of glutaraldehyde in aqueous solution, J. Chem. SOC. Chem. Commun., 10, 565, 1969.

5. Whipple, E. B. and Ruta, M., Structure of glutaraldehyde, J . Org. Chem., 39, 1666, 1974.

6. Holloway, C. E. and Dean, F. H., IT-NMR Study of aqueous glutaraldehyde equilibria, J. Pharmaceut. Sci., 64, 1078, 1975.

7. Tashima, T., Kawakami, U., Harada, M., Sakata, T., Satoh, N., Nakagawa, T., and Tanaka, H., Isolation and identification of new oligomers in aqueous solution of glutaraldehyde, Chem. Pharm. Bull., 35,4169, 1987.

8. Tashima, T., Kawakami, U., Satoh, N., Nakagawa, T., and Tanaka, H., Detection of im- purities in aqueous solution of glutaraldehyde by high performance liquid chromatography with a multi- channel photodiode m a y UV detector, J. Electron. Microsc., 36(3), 136, 1987.

9. Monsan, P., Puzo, G., and Mazarguil, H., Study on the mechanism of glutaraldehyde-proteins formation, Biochimie, 57, 1281, 1975.

10. Tashima, T., Kawakami, U., Harada, M., Imai, M., Satoh, N., Nakagawa, T., and Tanaka, H., Polymerization reaction in aqueous solution of glutaraldehyde containing trioxane-type oligomers under sterilizing conditions, Chem. Pharm. Bull., 37, 377, 1989.

11. Tashima, T., Imai, M., Kuroda, Y., Yagi, S., and Nakagawa, T., Structure of a new oligomer of glutaraldehyde produced by Aldol condensation reaction, J. Org. Chem., 56, 694, 1991.

12. Stanford Research Institute (SRI), U.S. Production - glutaraldehyde, HSDB record (October 1990), 1976.

13. Hazardous Substances Data Bank (HSDB), Glutar- aldehyde (Record #949), NLM, Toxnet computer file (October 10, 1990).

14. Harries, C. and Tank, L., Resolution of cyclopentene into the semialdehyde of glutaric acid or into glutaric dialdehyde, Chem. Ber., 41, 1701, 1908.

15. Smith, C. W. and Ballard, S. A. Production of Glutaraldehyde and C-Substituted Glutaraldehyde from Dihydro Pyrans, U.S. Patent 2546018 (assigned to Shell Development Co.), March 20, 1951.

16. Russell, A. D. and Hopwood, D., The biological uses and importance of glutaraldehyde, Prog. Med. Chem., 13, 271, 1976.

17. Gorman, S. P. and Scott, E. M., The state of the glutaraldehyde molecule in relation to its biocidal activity, J . Pharm. Pharmacol., 32, 131, 1980.

18. Union Carbide Corporation, Specialty Application Chemicals, Glutaraldehyde, industrial grade, Spe- cialty Chemicals Division, Danbury, CT, 1992.

19. Union Carbide Corporation, Ucarcide Preservatives, Union Carbide Product Information Booklet, Union Carbide Corporation, Danbury, CT, 1987.

20. Gorman, S. P., Scott, E. M., and Russell, A. D., A review. Antimicrobial activity, uses and mecha-

nism of action of glutaraldehyde, J . Appl. Bacteriol., 48, 161, 1980.

21. Volna, F., Maderova, E., Turzova, M., Cerey, K., and Szokolayova, J., Evaluation of antimicrobial efficacy and toxicity of glutaraldehyde, Bratisl. Lek. Listy, 90, 125, 1989.

22. Small, P. and Shapiro, M., Immunotherapy with glutaraldehyde treated tyrosine absorbed grass pollen in the treatment of allergic rhinitis, Ann. Allergy, 47, 443, 1981.

23. Small, P., Modified ragweed extract, J. Allergy Clin. Immunol., 69, 547, 1982.

24. Arya, S. C., Ashraf, S. J., and Pathak, V. P., Glutaraldehyde in whole-cell Bordella pertussis vaccine, Vaccine, 7, 486, 1989.

25. Stott, M., Chan, W. L., Mills, K. H. G., Page, M., Taffs, F., Cranage, M., Greenway, P., and Kitchen, P., Preliminary report: protection of cy- nomolgus macaques against immunodeficiency virus by fixed infected-cell vaccine, Lancet, 336, 1538, 1990.

26. Union Carbide Corporation, personal communication, Product Bulletins, Union Carbide Chemicals & Plastics Co., Inc., Bound Brook, NJ, 1990.

27. Miner, N. A., McDowell, J. W., Willcockson, G. W., Bruckner, N. I., Stark, R. L., and Whitmore, E. J., Antimicrobial and other properties of a new stabilized alkaline glutaraldehyde disinfectant/sterilizer, Am. J . Hosp. Pharm., 34, 376, 1977.

28. Stonehill, A. A., Krop, S., and Borick, P. M., Buffered glutaraldehyde - a new chemical sterilizing solution, Am. J. Hosp. Pharm., 20, 458, 1963.

29. Ballantyne, B. and Berman, B., Dermal sensitizing potential of glutaraldehyde: a review and recent observations, J. Toxicol. Cutaneous Ocul. Toxicol., 3, 251, 1984.

30. Hannah, D. R., Glutaraldehyde and calcium hy- droxide: a pulp dressing materials, Br. Dent. J., 132, 227, 1972.

31. London, I. D., Buffered glutaraldehyde solution for warts, Arch. Dermatol., 104, 96, 1971.

32. DesGroseillers, J. and Brisson, P., Localized epidermolysis bullosa. Report of two cases and evaluation of therapy with glutaraldehyde, Arch. Der- matol., 109, 70, 1974.

33. Gordon, B. I. and Maibach, H. I., Eccrine anhy- drosis due to glutaraldehyde, formaldehyde, and ion- tophoresis, J . Invest. Dermatol., 53, 436, 1969.

34. Gordon, H. H., Hyperhidrosis: treatment with glutaraldehyde, Cutis, 9, 375, 1972.

35. Gordon, H. H., Herpes zoster and herpes simplex: local therapy with glutaraldehyde, Cutis, 12, 918, 1973.

36. Gordon, H. H., Pitted keratolysis, forme fruste: a review and new therapies, Cutis, 15, 54, 1975.

37. Juhlin, L. and Hansson, H., Topical glutaraldehyde for plantar hyperhidrosis, Arch. Dermatol., 97, 327, 1968.

166

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

38. Maibach, H. I. and Prystowsky, S. D., Glutaral- dehyde (pentanedial) allergic contact dermatitis. Usage test on sole and antecubital fossa: regional variations in response, Arch. Dermatol., 113, 170, 1977.

39. Menne, T., Regional variations in contact sensitization, Cleve. Clin. J . Med., 54, 377, 1987.

40. Thoden van Velzen, S. K. and van den HooM, A., Long-term results of the implantation of glutaraldehyde-fixed tissue, Oral Surg., 44, 792, 1977.

41. Okamura, K., Chiba, C., Iriyama, T., Itoh, T., Maeta, H., Ijima, H., Mitsui, T., and Hori, M., Antigen depressant effect of glutaraldehyde for aortic heterografts with a valve, with special reference to a concentration right fit for the preservation of grafts, Surgery, 87, 170, 1980.

42. Gololobov, Y., Fursov, B. A., Mishchenko, B. P., Zaitsev, V. V., Dyatlov, V. A., Zaitsev, L. V., Rozanova, I. B., Tseitlina, E. A., Solomatina, L. A., et al., Effect of chemical treatment methods on calcification, hemocompatibility, and immuno- genic properties of xenopericardial bioprosthesis of cardiac valves, Dokl. Akad. Nauk. Ukr. SSR Ser. B: Geol. Khim. Biol. Nauki, ( l ) , 56, 1989.

43. Cole, A., Corry, P. M., and Langley, R., Effects of radiation and other agents on the molecular structure and organization of the chromosome, 23rd Annu. Symp. Fund. Cancer Res., Genetic Concepts and Neoplasia, Williams & Wilkins, Baltimore, 1970, 346.

44. Golomb, G., Schoen, F. J., Smith, M. S., Linden, J., Dixon, M., and Levy, R. J., The role of glutaraldehyde-induced cross-links in calcification of bovine pericardium used in cardiac valve bioprostheses, Am. J . Pathol., 127, 122, 1987.

45. Kaya, M., Grogan, J. B., Lentz, D., Tew, W., and Raju, S., Glutaraldehyde-preserved venous valve transplantation in the dog, J . Surg. Res., 45, 294, 1988.

46. Maranto, A. R. and Schoen, F. J., Alkaline phosphatase activity of glutaraldehyde-treated bovine pencardium used in bioprosthetic cardiac valves, Circ. Res., 63, 844, 1988.

47. Miyata, T., Tada, Y., Takagi, A., Sato, O., Oshima, A,, Idezuki, Y., and Shiga, J., A clino- pathologic study of aneurysm formation of glutaraldehyde-tanned human umbilical vein grafts, J . Vasc. Surg., 10, 605, 1989.

48. Nimni, M. E., Cheung, D., Strates, B., Kodama, M., and Sheikh, K., Chemically modified collagen: a natural biomaterial for tissue replacement, J . Biomed. Muter. Res., 21, 741, 1987.

49. Webb, C. L., Schoen, F. J., and Levy, R. J., -ropanehydroxydiphosphate to glu-

taraldehyde residues in pericardial bioprosthetic tissue: stability and calcification inhibition studies, Exp. Mol. Pathol., 50, 291, 1989.

50. Kligman, A. M. and Armstrong, R. C., Histologic response to inbadermal Zyderm and Zyplast (glutar-

. .

aldehyde cross-linked) collagen in humans, J . Der- matol. Surg. Oncol., 12, 351, 1986.

51. McPherson, J. M., Sawamura, S., and Armstrong, R., An examination of the biologic response to in- jectable, glutaraldehyde cross-linked collagen implants, J . Biomed. Muter. Res., 20, 93, 1986.

52. Stegman, S. J., Chu, S., Bensch, K., and Armstrong, R., A light and electron microscopic evaluation of Zyderm collagen and Zyplast implants in aging human facial skin. A pilot study, Arch. Der- matol., 123, 1644, 1987.

53. Noishiki, Y. and Miyata, T. Antithrombogenic Heparinized Collagen-Based Medical Materials, U.S. Patent 4704131 (assigned to Koken Co., Ltd., Ja- pan), Nov. 3, 1987.

54. Duval, J. L., Sigot-Luizard, M. F., and Sigot, M., Studies of endothelial cells adhesion to glutaraldehyde or carbodiimide crosslinked proteins, Adv. Biomater. Biol. Biomech. Perf. Biomater., 6, 269, 1986.

55. Warocquier-Clerout, R., Sigot-Luizard, M. F., and Legendre, J. M., F.p.1.c. analysis of the leak- age products of proteins crosslinked on Dacron@ vas- cular prostheses, Biomaferials, 8, 118, 1987.

56. Batista, 0. A., Protein Hydrogels for Contact Len- ses, Surgical Goods and Prosthetics, U.S. Patent 4416814, November 22, 1983.

57. Corry, W. D. and Meiselman, H. J., Modification of erythrocyte physicochemical properties by millimolar concentrations of glutaraldehyde, Blood Cells, 4, 465, 1978.

58. Hayat, M. A., Types of fixatives. Aldehydes - glutaraldehyde, in Principles and Techniques of Elec- tron Microscopy. Biological Applications, Vol. 1, Van Nostrand Reinhold, New York, 1970, 67.

59. Sabitini, D. D., Bensch, K., and Barnett, R. J., New means of fixation for electron microscopy and histochemistry, Anat. Rec., 142, 274, 1962.

60. DeJong, D. W., Olson, A. C., and Jansen, E. F., Glutaraldehyde activation of nuclear phosphatase in cultured plant cells, Science, 155, 1672, 1967.

61. Jordan, W. P., Dahl, M. V., and Albert, H. L., Contact dermatitis from glutaraldehyde, Arch. Der- matol., 105, 94, 1972.

62. Turner, T. W., An adverse reaction to glutaraldehyde, Med. J . Aust., 2, 14, 1983.

63. Murray, W. J. and Ruddy, M. P., Toxic eye injury during induction of anesthesia, South. Med. J. , 78, 1012, 1985.

64. Avery, J. K., The good doctor - the bad result, J . Tenn. Med. Assoc., 78, 440, 1985.

65. Binding, N. and Witting, U., Exposure to formaldehyde and glutaraldehyde in operating theatres, Int. Arch. Occup. Environ. Health, 62, 233, 1990.

66. American Conference of Governmental Industrial Hygenists, Inc., Documentation of Threshold Limit Values and Biological Exposure Indices, 5th ed., Glutaraldehyde, American Conference of Govern-

167

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

mental Industrial Hygienists, Inc., Cincinnati, OH, 1986, 285.

67. Bardazzi, F . , Melino, M., Alagna, G., and Veronesi, S., Glutaraldehyde dermatitis in nurses, Contact Dermatitis, 14, 319, 1986.

68. Benson, W. G., Case report; exposure to glutaraldehyde, J . SOC. Occup. Med., 34, 63, 1984.

69. Burge, P. S., Occupational risks of glutaraldehyde, Br. Med. J., 299, 342, 1989.

70. Corrado, 0. J., Osman, J., and Davies, R. J., Asthma and rhinitis after exposure to glutaraldehyde in endoscopy units, Hum. Toxicol., 5, 325, 1986.

71. Crandall, M. S., Health Hazard Evaluation Report HEA 86-226-1 769, Montgomery Hospital, Norris- town, Pennsylvania, National Institute for Occupa- tional Safety and Health, Cincinnati, OH, Hazard Evaluations and Technical Assistance Branch, 1987,

72. Di Prima, T., De Pasquale, R., and Nigro, M., Contact dermatitis from glutaraldehyde, Contact Der- matitis, 19, 219, 1988.

73. Fisher, A. A., Reactions to glutaraldehyde with particular reference to radiologists and x-ray technicians, Cutis, 28, 113, 1981.

74. Goncalo, S., Menzes Brandao, F., Pecegueiro, M., Moreno, J. A., and Sousa, I., Occupational contact dermatitis to glutaraldehyde, Contact Dermatitis, 10, 183, 1984.

75. Gunter, B. J., Health Hazard Evaluation Report HETA 87-1 76-1826, St. James Community Hospital, Butte, Montana, NIOSH, Cincinnati, OH, Hazard Evaluations and Technical Assistance Branch, 1987,

76. Hansen, K. S., Glutaraldehyde occupational dermatitis, Contact Dermatitis, 9, 81, 1983.

77. Holderman, R. D., Parlette, H. L., Terezhalmy, G. T., Pelleu, G. B., and Taybos, G. M., An evaluation of the efficacy and imtability of Spori- cidin@ as a hand dip, Oral Surg. Oral Med. Oral Pathol., 62, 142, 1986.

78. Jachuck, S. J., Bound, C. L., Steel, J., and Blain, P. G., Occupational hazard in hospital staff exposed to 2 per cent glutaraldehyde in an endoscopy unit, J . SOC. Occup. Med., 39, 69, 1989.

79. Lyon, T. C., Allergic contact dermatitis due to Cidex, Oral Surg., 32, 895, 1971.

80. National Institute of Occupational Safety and Health, Symptoms of irritation associated with exposure to glutaraldehyde - Colorado, MMWR, 36( 12), 190, 1987.

81. Pryor, P., Health Hazard Evaluation Report HETA 85-257-1 791, Mercy Medical Center, Denver, Col- orado, National Institute for Occupational Safety and Health, Cincinnati, OH, Hazard Evaluations and Technical Assistance Branch, 1987, PB87-233049 XAB .

82. Trigg, J., A sensitive issue, Nursing Mirror, 159(13), vi, 1984.

PB87-205894/XAB.

PB88-1627631XAB.

83. Salisbury, S., Health Hazard Evaluation Report HETA 83-284-1536, Dialysis Clinic, Inc., Atlanta, GA, National Institute for Occupational Safety and Health, Cincinnati, OH, 1984, PB85-20775 I/XAB.

84. Straughn, J. C. and Barker, F. B., Avoiding glutaraldehyde irritation of the mucous membranes, Gastrointest. Endosc., 33, 396, 1987.

85. Wiggins, P., McCurdy, S. A,, and Zeidenberg, W., Epistaxis due to glutaraldehyde exposure, J . Oc- cup. Med., 31, 854, 1989.

86. Gad, S. C., A scheme for the prediction and ranking of relative potencies of dermal sensitizers based on data from several systems, J. Appl. Toxicol., 8, 361, 1988.

87. Marzulli, F. N. and Maibach, H. I., The use of graded concentrations in studying skin sensitizers: experimental contact sensitization in man, Food Cos- met. Toxicol., 12, 219, 1974.

88. Douglas, W. H. J. and Spilman, S. D., In vitro ocular imtancy testing, in Alternative Methods in Toxicology, Vol. 1, Prod. Saf. Eval. 13, tioldberg, A. M., Ed., Mary Ann Liebert Inc., New York, 1983, 205.

89. Maibach, H. I., Glutaraldehyde: cross-reactions to formaldehyde?, Contact Dermatitis, 1, 326, 1975.

90. Dilley, G. J. and Courts, F. J., Immunological response to four pulpal medicaments, Pediatr. Dent., 3, 179, 1981.

91. Jaworsky, C., Taylor, J. S., Evey, P., and Handel, D., Allergic contact dermatitis to glutaraldehyde in a hair conditioner, Cleve. Clin. J. Med., 54, 443, 1987.

92. %-Gravenmade, E. J., Some biochemical consid- erations of fixation in endodontics, J. Endodont., 1, 233, 1975.

93. Davis, M. J., Myers, R., and Switkes, M. D., Glutaraldehyde: an alternative to formocresol for vital pulp therapy, J. Dent. Child., 49, 176, 1982.

94. Wemes, J. C., Jansen, H. W. B., Purdell-Lewis, D., and Boering, G., Histologic evaluation of the effect of formocresol and glutaraldehyde on the peripheral tissues after orthodontic treatment, Oral Surg., 54, 329, 1982.

95. Munksgaard, E. C., Study of polymer-dentin adhesion by means of various adhesives and GLUMA@, J. Biomater. Dent., 3, 11, 1987.

96. Bayne, S. C., personal communication, School of Dentistry, University of North Carolina, Chapel Hill, 1992.

97. Arenholt-Bindslev, D., Horsted-Bindslev, P., and Philpsen, H. P., Toxic effects of two dental materials on human buccal epithelium in vitro and monkey buccal mucosa in vivo, Scand. J. Dent. Res., 95, 467, 1987.

98. Horsted-Bindslev, P., Monkey pulp reactions to cavities treated with Gluma Dentin Bond and restored with a microfilled composite, Scand. J. Dent. Res., 95, 347, 1987.

168

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

99. Arends, J., Ogaard, B., Ruben, J., Wemes, J., and Rolla, G., Influence of glutaraldehyde on dentin demineralization in vitro and in vivo, Scand. J . Dent. Res., 97, 297, 1989.

100. Dankert, J., %Gravenmade, E. J., and Wemes, J. C., Diffusion of formocresol and glutaraldehyde through dentin and cementum, J . Endodont., 2, 42, 1976.

101. Wemes, J. C., Purdell-Lewis, D., Jongebloed, W., and Vaalburg, W., Diffusion of carbon- 14-labeled formocresol and glutaraldehyde in tooth structures, Oral Surg. Oral Med. Oral Pathol., 54, 341, 1982.

102. Lekka, M., Hume, W. R., and Wolinsky, L. E., Comparison between formaldehyde and glutaraldehyde diffusion through the root tissues of pulpotomy- treated teeth, J . Pedod., 8, 185, 1984.

103. Myers, D. R., Pashley, D. H., Lake, F. T., Burnham, D., Kalathoor, S., and Waters, R., Sys- temic absorption of 14C-glutaraldehyde from glutaraldehyde-treated pulpotomy sites, Pediatr. Dent., 8, 134, 1986.

104. Speer, D. P., Chvapil, M., Eskelson, C. D., and Ulreich, J., Biological effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomater- ials, J . Biomed. Muter. Res., 14, 753, 1980.

105. LeMoan, G., Chaigneau, M., Chastagnier, and Pham, H. C., Persistence of residues during treatment of surgical materials with glutaraldehyde, Ann. Falsif. Exp. Chim. Toxicol., 76(823), 463, 1983.

106. Wiebe, D., Megerman, J., L’Italien, G. J., and Abbott, W. M., Glutaraldehyde release from vas- cular prostheses of biologic origin, Surgery, 104,26, 1988.

107. Gendler, E., Gendler, S., and Nimni, M. E., Toxic reactions evoked by glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis, J . Biomed. Muter. Res., 18, 727, 1984.

108. National Research Council, Committee on Alde- hydes, Formaldehyde and Other Aldehydes, National Academy of Sciences Press, Washington, D.C., 1981, 243.

109. St. Clair, M. B. G., Bermudez, E., Gross, E. A., Butterworth, B. E., and Recio, L., Evaluation of genotoxic potential of glutaraldehyde, Environ. Mol. Mutagen., 18, 113, 1991.

1 10. Gross, E. A., Morgan, K. T., Mellick, P. W., and Kari, F. W., Glutaraldehyde-induced pathology and cell proliferation in the rat nasal cavity, Toxicologist, 11(1), 182, 1991 (Abstr. 666).

11 1. Carson, F. L., Histotechnology. A Self-Instructional Text, American Society of Clinical Pathologists, ASCP Press, Chicago, 1990, 14.

112. Crookham, J. N. and Dapson, R. W., Hazardous chemicals in the histopathology laboratory, in Reg- ulations, Risks, Handling & Disposal, 1st ed., An- atech, Battle Creek, MI, 1991, 94.

113. Young, J. A., Handling of hazardous chemicals, in Electron Microscopy Safety, Barber, V. C. and Clay-

ton, D. L., Eds., San Francisco Press, San Francisco, 1985, 13.

114. Occupational Safety and Health Administration, Air Contaminants, Final Rule, Fed. Regist., 54(12), 2332, 1989.

115. Nichiporenko, V. P., Stankevich, V. V., Orlovskii, V. M., Kruchinina, A. A., Maktaz, E. D., Gorshkova, L. I., Botvinova, L. E., Yakimuk, L. P., et al., Experimental determination of maximum allowable concentrations of glutaraldehyde in water bodies, Gig. Sanit., 3, 77, 1987.

116. Sidorov, K. K., Maximum permissible concentrations of harmful substances in the air of the working zone confirmed by the Ministry of Public Health USSR in 1983, Gig. Tr. Prof. Zabol., 3, 53, 1986.

1 17. Health Care Financing Administration (HCFA), HHS , Medicare Program, protocol for the reuse of dialysis bloodlines, Fed. Regist., 55(85), 18331, 1990.

118. Food and Drug Administration, Health and Human Services, Indirect food additives: paper and paperboard components. Final rule, Fed. Regist., 55(151), 31824, 1990.

119. Mine Safety and Health Administration, Department of Labor, Hazard communication. Proposed rule, Fed. Regist., 55(213), 46400, 1990.

120. Reifenrath, W. G.,Prystowsky, S. D., Nonomura, J. H., and Robinson, P. B., Topical glutaraldehyde- percutaneous penetration and skin irritation, Arch. Dermatol. Res., 277, 242, 1985.

121. Tallant, M. J., Frantz, S. W., and Ballantyne, B., Evaluation of the in vitro skin penetration of glutaraldehyde using the rat, mouse, rabbit, guinea pig and human skin, Toxicologist, 10, 256, 1990 (Abstr. No. 1022).

122. Ballantyne, B., Review of Toxicological Studies and Human Health Effects - Glutaraldehyde, Union Car- bide Corporation, Danbury, CT, 1986, l .

123. Packer, L. and Greville, G. D., Enzyme-linked oxidation of glutaraldehyde by rat liver mitochondria, FEBS Lett., 3, 112, 1969.

124. Smith, L. and Packer, L., Aldehyde oxidation in rat liver mitochondria, Arch. Biochem. Biophys., 148, 270, 1972.

125. Karp, W. B., Korb, P., and Pashley, D., The oxidation of glutaraldehyde by rat tissues, Pediatr. Dent., 9, 301, 1987.

126. Jones, G. L. and Teng, Y. S., A chemical and enzymological account of the multiple forms of human liver aldehyde dehydrogenase. Implications for ethnic differences in alcohol metabolism, Biochim. Biophys. Acta, 745, 162, 1983.

127. Antonenkov, V. D., Pirozhkov, S. V., and Panchenko, L. F., On the role of microsomal aldehyde dehydrogenase in metabolism of aldehydic products of lipid peroxidation, FEBS Lett., 224, 357, 1987.

128. Pirozhkov, S. V. and Panchenko, L. F., Role of aldehyde dehydrogenase in malonic dialdehyde me-

169

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

129.

130.

131.

tabolism in rat liver, Biokhimiya (Moscow), 53(9), 1443, 1988. Forte-McRobbie, C. M. and Pietruszko, R., Pu- rification and characterization of human liver “high Km” aldehyde dehydrogenase and its identification as glutamic-semialdehyde dehydrogenase, J. Biol. Chem., 261, 2154, 1986. Ryzlak, M. T. and Pietruszko, R., Human brain “high Km” aldehyde dehydrogenase: purification, characterization, and identification as NAD+-dependent succinic semialdehyde dehydrogenase, Arch. Biochem. Biophys., 266, 386, 1988. Besrat, A., Polan, C. E., and Henderson, L. M., Mammalian metabolism of glutaric acid, J. Biol. Chem., 244, 1461, 1969.

143. Hemminki, K. and Suni, R., Site of reaction of glutaraldehyde and acetaldehyde with nucleosides, Arch. Toxicol., 55, 186, 1984.

144. Hopwood, D., The reactions of glutaraldehyde with nucleic acids, Histochem. J., 7, 267, 1975.

145. St. Clair, M. B. G., Bermudez, E., Gross, E. A., Recio, L., Morgan, K. T., and Butterworth, B. E., Evaluation of the genotoxic and cytotoxic potential of glutaraldehyde, Environ. Mol. Mutagen., 17 (Suppl. 19), 71, 1991 (Abstr. No. 254).

146. Devro, Inc., Glutaraldehyde oral toxicity tests indicate no related lesions, Food Chem. News, 26(8), 42, 1984.

147. Spencer, P. S., Bischoff, M. C., and Schaumburg, H. H., On the specific molecular configuration of

132. Meister. A.. Intermediarv metabolism of amino acids, neurotoxic aliphatic hexacarbon compounds causing

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

I .

in Biochemistry of the Amino Acids, Vol. 2, 2nd ed., Academic Press, New York, 1965, 858, 941. Goordman, S. I. and Kohlhoff, J. G., Glutaxic aciduria: inherited deficiency of glutaryl-CoA dehydrogenase activity, Biochem. med. , 13, i38, i975. Peters, K. and Richards, F. M., Chemical cross- linking: reagents and problems in studies of mem- brane structure, Annu. Rev. Biochem., 46,523, 1977. Habeeb, A. F. S. A. and Hiramoto, R., Reaction of proteins with glutaraldehyde, Arch. Biochem. Bio- phys., 126, 16, 1968. Hopwood, D., Allen, C. R., and McCabe, M., Reactions between glutaraldehyde and various proteins. An investigation of their kinetics, Histochem. J., 2, 137, 1970. Monsan, P., Puzo, G., and Mazarguil, H., Study on the mechanism of action of glutaraldehyde, in Analysis of Control of Immobilized Enzyme Systems, Thomas, D. and Kernevez, J.-P., Eds., Elsevier, New York, 1976, 275. Schauenstein, E., Esterbauer, H., and Zollner, H., Dicarbonyl compounds, in Aldehydes in Biolog- ical Systems, Pion Limited, London, 1977, 140. Hardy, P. M., Nicholls, A. C., and Rydon, H. N., The nature of the cross-linking of proteins by glutaraldehyde. I. Interaction of glutaraldehyde with the amino-groups of 6-aminohexanoic acid and of [alpha]-N-acetyl-lysine, J . Chem. SOC. Perkin I, p. 958, 1976. Hardy, P. M., Hughes, G. J., and Rydon, H. N., Identification of a 3-(2-piperidyl)pyridinium derivative (“anabilysine”) as a cross-linking entity in a glutaraldehyde-treated protein, J . Chem. SOC. Chem. Commun., 759, 1977. Johnson, T. J. A., Glutaraldehyde fixation chem- istry: oxygen-consuming reactions, Eur. J. Cell Biol., 45, 160, 1987. Cheung, D. T. and Nimni, M. E., Mechanism of crosslinking of proteins by glutaraldehyde I: reaction with model compounds, Connect. Tiss. Res., 10, 187, 1982.

central-peripheral distal axonopathy , Toxicol. Appl. Pharmacol., 44, 17, 1978.

148. Descotes, J., Identification of contact allergens: the mouse ear sensitization assay, J . Toxicol. Cutaneous Bcul. Toxicol., 7, 263, 1988.

149. Ballantyne, B., Garman, R. H., Greenspan, B. J., and Myers, R. C., Acute toxicity and irritancy of glutaraldehyde, Toxicologist, 5, 204, 1985 (Abstr. No. 813).

150. Stern, M. L., Holsapple, M. P., McCay, J. A., and Munson, A. E., Contact hypersensitivity response to glutaraldehyde in guinea pigs and mice, Toxicol. Ind. Health, 5 , 31, 1989.

15 1. Ranly, D. M., Horn, D., and Zislis, T., The effect of alternatives to formocresol on antigenicity of proteins, J . Dent. Res., 64, 1225, 1985.

152. Whitehouse, M. W., Beck, F. J., and Kacena, A., Some (pharmacological) properties of chloracetal- dehyde, an oxidation product and potential metabolite of cyclophosphamide, Agents Actions, 4, 34, 1974.

153. Uemitsu, N., Kawasaki, H., Furuhashi, T., Miyoshi, K., Ohtaka, T., Nomura, A., Hasegawa, T., Shimizu, Y., and Nakazawa, M., Acute and subacute toxicity studies and local imtation study of glutaraldehyde, Oyo Yakuri, 12, 11, 1976.

154. Varpela, E., Otterstrom, S., and Hackman, R., Liberation of alkalinized glutaraldehyde by respirators after cold sterilization, Actu Anaesth. Scund., 15, 291, 1971.

155. St. Clair, M. B., Gross, E. A., and Morgan, K. T., Interaction of glutaraldehyde with nasal epithelium, Toxicologist, 9(1), 37, 1989 (Abstr. No. 145).

156. St. Clair, M. B., Gross, E. A., and Morgan, K. T., Pathology and cell proliferation induced by intra-nasal instillation of aldehydes in the rat: comparison of glutaraldehyde and formaldehyde, Toxicol. Pathol., 18, 353, 1990.

157. Morgan, K. T., Jiang, X. Z., Starr, T. B., and Kearns, W. D., More precise localization of nasal tumors associated with chronic exposure of F-344 rats

170

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

to formaldehyde gas, Toxicol. Appl. Pharmacol., 82, 264, 1986.

158. Monticello, T. M., Miller, F. J., and Morgan, K. T., Regional increases in rat nasal respiratory epithelial cell proliferation following acute and subacute inhalation of formaldehyde, Toxicol. Appl. Phar- macol., 111, 409, 1991.

159. Gross, E. A., Mellick, P., Kari, F., and Morgan, K. T., Histopathology and cell replication in the nasal epithelium of rats and mice exposed to glutaraldehyde vapor, Toxicology, 12, 399, 1992 (Abstr. 1575).

160. Morgan, K. T. and Monticello, T. M., Formal- dehyde toxicity: respiratory epithelial injury and repair, in Biology, Toxicology, and Carcinogenesis of Respiratoly Epithelium, Thomassen, D. G . and Net- tesheim, P. , Eds., Hemisphere, New York, 1990, 155.

161. Greenspan, B. J., Ballantyne, B., Fowler, E. H., and Snellings, W. M., Subchronic inhalation toxicity of glutaraldehyde, Toxicologist, 5, 29, 1985 (Abstr. No. 115).

162. James, T. N. and Bear, E. S., Aldehyde structure and cardiac effects, J . Pharmacol. Enp. Ther., 163, 300, 1968.

163. Harner, C. D., Fu, F. H., Mason, G. C., Wwinger, H. A., and Rabin, B. S., Cidex-induced synovitis, Am. J . SportsMed., 17, 96, 1989.

164. Kuroki, K., Ohsumi, T., and Murakami, Y., Ef- fect of glutaraldehyde on cultured cells - restraining effect on multiplication of L cells, Nippon Yakuri- gaku Zasshi, 88, 65, 1986.

165. Kuroki, K. and Oshumi, T., Morphological observations of cultured L cells exposed to formaldehyde or glutaraldehyde, Kyushu Shika Gakkai, Zas- shi, 39, 663, 1985.

166. Kuroki, K. and Ohsumi, T., Study on cytotoxicity of formaldehyde and glutaraldehyde by phase contrast microscopy, Kyushu Shika Gakkai Zasshi, 39, 91, 1985.

167. Sentein, P., Action of glutaraldehyde and formaldehyde on segmentation mitoses. Inhibition of spin- dle and astral fibres, centrospheres blocked, Exp. Cell Res., 95, 233, 1975.

168. Ates, Y. and Sentien, P., A comparison between the action of colchicine, chloralhydrate, glutaraldehyde, and polyurethane on the ultrastructure of segmentation mitoses in a newt, Biol. Cell., 33, 129, 1978.

169. Sentein, P. and Le Coq, D., Enhanced polyploidy by glutaraldehyde in cultured HL60 leukemic cells, Leuk. Res., 10, 575, 1986.

170. Harke, H.-P. and Sporkenbach-HoeMer, J., Stud- ies on release of toxic components from disinfectant’s solutions into the air, Zentralbl. Bakteriol. Mikrobiol. Hyg. Ser. B Umwelthyg. Kranknhaushyg. Ar- beitshyg. Praev. Med., 185, 421, 1988.

171. St. Clair, M. B. G., Bermudez, E., Recio, L., Gross, E. A., and Morgan, K. T., In vitro studies

of glutaraldehyde toxicity and mutagenicity, Toxi- cologist, 10, 96, 1990 (Abstr. No. 383).

172. Oesch, F., Janik-Schmitt, B., Ludewig, G., Glatt, H., and Wieser, R. J., Glutaraldehyde-fixed transformed and non-transformed cells induce contact-dependent inhibition of growth in non-transformed C3W 10T1/2 mouse fibroblasts, but not in 3-methylcholanthrene-transformed cells, J . Cell Biol., 43, 403, 1987.

173. D’Ovidio, N. G., Jesseph, J. M., and LeVeen, H. H., Prevention of implantation cancer with dilute solutions of glutaraldehyde, Surg. Forum, 32, 429, 1981.

174. Mondal, S., Embleton, M. J., Marquardt, H., and Heidelberger, C., Production of variants of decreased malignancy and antigenicity from clones transformed in vitro by methylcholanthrene, Int. J . Cancer, 8, 410, 1971.

175. Iwata-Dohi, N., Esumi-Kurisu, M., Ikenami, M., Sadatsune, K., Mizuno, D., and Yamazaki, M., Enhanced susceptibility of glutaraldehyde-treated tumor cells to antibody-dependent macrophage-mediated cytolysis, Cancer Res. , 42, 3196, 1982.

176. Kataoka, T., Oh-hashi, F., Tsukagoshi, S., and Sakuri, Y., Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A, Cancer Res., 37, 964, 1977.

177. Ben-Efraim, S., Ophir, R., and Relyveld, E. H., Tumour immunoprophylaxis in mice using glutaraldehyde-treated syngeneic myeloma cells, Br. J . Can- cer, 43, 554, 1981.

178. Nerkar, D. P., Chander, R., Bandekar, J. R., and Lewis, N. F., Induction of resistance to ascites tumor in mice with MFS-180 cells treated with glutaraldehyde, lipopolysaccharide, and concanavalin A, Cancer Res., 41, 2922, 198 1.

179. Price, M. R., Gerlier, D., and Law, L. W., Re- sistance of the Meth A sarcoma-associated rejection antigen to inactivation with glutaraldehyde, Br. J . Cancer, 44, 584, 1981.

180. Guillochon, D., Esclade, L., and Thomas, D., Ef- fect of glutaraldehyde on haemoglobin: oxidation- reduction potentials and stability, Biochem. Phar- macol., 35, 317, 1986.

181. Bellelli, A., Benedetti, P. L., Coletta, M., Ippoliti, R., and Brunori, M., Human erythrocytes cross- linked with glutaraldehyde-general properties and significance as a blood substitute, Biochem. Biophys. Res. Commun., 156, 970, 1988.

182. Davis, T. A., Asher, W. J., and Wallace, H. W., Artificial red cells with crosslinked hemoglobin membranes, Appl. Biochem. Biotechnol., 10, 123, 1984.

183. Fricova, V., Pristoupil, T. I., Kramlova, M., and Paluska, E., Human hemoglobin modified by pyr- idoxal-5-phosphate and glutaraldehyde in the presence of serum albumin. I. Preparation and chemical

171

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

properties of a new variant of infusable solution, Biol- ogia (Bratislava), 41, 697, 1986.

184. Fricova, V., Paluska, E., Pristoupil, T. I., Kramlova, M., Ulrych, S., Sterba, O., and Jojkova, K., Human hemoglobin polymerized with glutaraldehyde. Physicochemical properties and rate of elimination from blood channel, Cesk. Farm., 32, 27, 1983.

185. Constantinescu, A. and Margineanu, D. G., Glu- taraldehyde effect on the osmotic fragility and rate of hemolysis of human erythrocytes: a kinetic study, Arch. Int. Physiol. Biochim., 90, 277, 1982.

186. Walter, H. and Krob, E. J., Fixation with even small quantities of glutaraldehyde affects red blood cell surface properties in a cell- and species-dependent manner. Studies by cell partitioning, Biosci. Rep., 9, 721, 1989.

187. Cohen, R. M. and McLellan, C., The effects of glutaraldehyde cross-linking on the function of the adenylate cyclase complex of turkey erythrocytes, Life Sci., 38, 2151, 1986.

188. Desoize, B., Jardillier, J. C., Kanoun, K., Guerin, D., and Levy, M. C., In-vitro cytotoxic activity of cross-linked protein microcapsules, J . Pharm. Phar- macol., 38, 8, 1986.

189. Zocchi, E., Tonetti, M., Polvani, C., Guida, L., Benatti, U., and DeFlora, A., In vivo liver and lung targeting of adriamycin encapsulated in glutaraldehyde-treated murine erythrocytes, Biotechnol. Appl. Biochem., 10, 555, 1988.

190. Margineanu, D. G., Katona, E., and Popa, J., Kinetics of nerve impulse blocking by protein cross- linking aldehydes. Apparent critical thermal points, Biochim. Biophys. Acta, 649, 581, 1981.

191. Popa, J., Katona, E., and Margineanu, D. G., Glutaraldehyde effects on nerve electrical activity, Rev. Roum. Biochim., 18, 275, 1981.

192. Morgan, P. F. and Stone, T. W., Use of glutaraldehyde in the termination of [3H]-adenosine uptake in synaptosomes, IRCS Med. Sci., 13, 505, 1985.

193. Serikyaku, S. and Ishitani, R., Glutaraldehyde pretreatment blocks temperature-induced high-affinity ['Hltryptamine binding, Life Sci., 42, 207, 1988.

194. Wade, M. J., Friedman, L., and Ross, V. C., Biochemical and toxicological effects of glutaraldehyde, FDA By-Lines, 12(1), 7, 1982.

195. Watts, P., Non-mutagenicity of glutaraldehyde, Food Chem. Toxicol., 22, 1024, 1984.

196. Hemminki, K., Falck, K., and Vainio, H., Com- parison of alkylation rates and mutagenicity of directly acting industrial and laboratory chemicals, Arch. Toxicol., 46, 277, 1980.

197. Von der Hude, W., Behm, C., Guertler, R., and Basler, A., Evaluation of the SOS chromotest, Mu- tat. Res., 203, 81, 1988.

198. Yoon, J. S., Mason, J. M., Valencia, R., Woodruff, R. C., and Zimmering, S., Chemical mutagenesis testing in Drosophila. IV. Results of 45 coded compounds tested for the National Toxicology Program, Environ. Mutagen., 7, 349, 1985.

199. Haworth, S., Lawlor, T., Mortelmans, K., Speck, W., and Zeiger, E., Salmonella mutagenicity test results for 250 chemicals, Environ. Mutagen., Suppl. 1 , 3, 1983.

200. Levin, D. E., Hollstein, M., Christman, M. F., Schwiers, E. A., and Ames, B. N., A new Sal- monella tester strain (TA102) with A-T base pairs at the site of mutation detects oxidative mutagens, Proc. Natl. Acad. Sci. U.S.A. , 79, 7445, 1982.

201. Marnett, L. J., Hurd, L. K., Hollstein, M. C., Levin, D. E., Esterbauer, H., and Ames, B. N., Naturally occurring carbonyl compounds are mutagens in Salmonella tester strain TA104, Mutat. Res., 148, 25, 1985.

202. Ruiz-Rubio, M., Alejandre-Duran, E., and Pueyo, C., Oxidative mutagens specific for A-T base pairs induce forward mutations to L-arabinose resistance in Salmonella typhimurium,Mutat. Res., 147,153,1985.

203. Sakagami, Y., Yamazaki, H., Ogasawara, N., Yokoyama, H., Ose, Y., and Sato, T., The evaluation of genotoxic activities of disinfectants and their metabolites by the umu test, Mutat. Res., 209, 155, 1988.

204. Sakagami, Y., Yamasaki, K., Yokoyama, H., Ose, Y., and Sato, T., DNA repair test of disinfectants by liquid rec-assay, Mutat. Res., 193, 21, 1988.

205. McGregor, D. B., Brown, A., Cattanach, P., Edwards, I., McBride, D., and Caspary, W. J., Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay 11. 18 coded chemicals, Environ. Mol. Mutagen., 11, 91, 1988.

206. Zimmering, S., Mason, J. M., and Valcenia, R., Chemical mutagenesis testing in Drosophila. VII. Re- sults of 22 coded compounds tested in larval feeding experiments, Environ. Mol. Mutagen., 14,245, 1989.

207. Tamada, M., Sasaki, S., Kadono, Y., Kato, S., Amitani, M., Ogasahara, Y., Tamura, T., and Sato, N., Mutagenicity of glutaraldehyde in mice, Bobkin Bobai, 6, 62, 1978.

208. Levy, R. J., Schoen, F. J., Levy, J. T., Nelson, A. C., Howard, S. L., and Oshry, L. J., Biologic determinants of dystrophic calcification and osteo- clash deposition in glutaraldehyde preserved porcine aortic valve leaflets implanted subcutaneously in rats, Am. J. Pathol., 113, 143, 1983.

209. Slesinski, R. S., Hengler, W. C., Guzzie, P. J., and Wagner, K. J., Mutagenicity evaluation of glutaraldehyde in a battery of in vitro bacterial and mammalian test systems, Food Chem. Toxicol., 21, 621, 1983.

210. Galloway, S. M., Bloom, A. D., Resnick, M., Margolin, B. H., Nakamura, F., Archer, P., and Zeiger, E., Development of a standard protocol for in vitro cytogenetic testing with Chinese hamster ovary cells: comparison of results for 22 compounds in two laboratories, Environ. Mutagen., 7, 1, 1985.

211. Mirsalis, J., Tyson, K., Loh, E., Bakke, J., Hamilton, C., Spak, D., Steinmetz, K., and Spalding, J., Induction of unscheduled DNA synthesis (UDS) and cell proliferation in mouse and rat

1 72

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

hepatocytes following in vivo treatment, Environ. Mutagen., 7 (Suppl. 3) 73, 1985 (Abstr.).

212. Devro, Inc., Glutaraldehyde in vitro tests reported to show no mutagenicity, Food Chem. News, 25(32), 18, 1983.

213. Hemminki, K., Kyyroenen, P., and Lindbohm, M., Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome, J . Epidemiol. Commun. Health, 39, 141, 1985.

214. Hemminki, K., Mutanen, P., Saloniemi, I., Miemi, M. L., and Vainio, H., Spontaneous abortions in hospital staff engaged in sterilizing instruments with chemical agents, Br. Med. J. , 285, 1461, 1982.

215. Marks, T. A., Worthy, W. C., and Staples, R. E., Influence of formaldehyde and Sonicide (potentiated acid glutaraldehyde) on embryo and fetal development in mice, Teratology, 22, 51, 1980.

216. BASF Corp., Substantial Risk Report on Glutaral- dehyde, EPA number: 83HQ-0990-1008, U.S. EPAI OPTS, Public Files 89-900000423 and 88-900000179, 1990.

217. Johnson and Johnson Medical, Inc., Material Safety Data Sheet CIDEX FORMULA 7* Long-life activated dialdehyde solution/activator vial, P.O. Box 130, Arlington, TX, 1990.

218. Johnson and Johnson Medical, Inc., Material Safety Data Sheet CIDEX* Activated Dialdehyde Solution/ Activator Vial, P.O. Box 130, Arlington, TX, 1990.

219. Johnson and Johnson Medical, Inc., Cidex sterilizing/ disinfecting systems, P.O. Box 130, Arlington, TX, 1988.

220. Ackerman, S. B., Stokes, G. L., Swanson, R. J., Taylor, S. P., and Fenwick, L., Toxicity testing for human in vitro fertilization programs, J . In Vitro Fertil. Embryo. Transfer., 2, 132, 1985.

221. Fabro, S., Shull, G., and Brown, N. A., The relative teratogenic index and teratogenic potency: proposed components of developmental toxicity risk assessment. Teratogen. Carcinogen. Mutagen., 2, 61, 1982.

222. Rogers, J. D., Rate constant measurements for the reaction of the hydroxyl radical with cyclohexene, cyclopentene, and glutaraldehyde, Environ. Sci. Technol., 23, 177, 1989.

223. Schefer, W., Testing of the toxicity effect from waste water components for biological purification stages, Textilveredlung, 12(6), 247, 1977.

224. Evans, A. P., Reactions of Glutaraldehyde and Suc- cinaldehyde with Compounds Containing Replace- able Hydrogen Atoms, Ph.D. dissertation, University Maryland, MD, 1969.

225. National Institute of Occupational Safety and Health, NIOSH Manual of Analytical Methods, Method 253 1, May 15, 1989.

226. Thompson, R. P. and Damanczuk, R. A. Schiff Test for Rapid Detection of Low Levels of Alde-

227.

228.

229.

230.

231.

232,

233.

hydes, U.S. Patent 4753891 (assigned to AKZO N.V.), June 28, 1988. Purnell, C. J., Bagon, D. A., and Warwick, C. J., The determination of organic contaminant concentrations in workplace atmospheres by high-performance liquid chromatography, Anal. Tech. Environ. Chem., 2, 203, 1981. Reitz, B., Determination of three aldehydes in the air of working environments, Anal. Lett., 18(A19), 2369, 1985. Occupational Safety and Health Administration, OSHA Procedure for Glutaraldehyde, ID-64, Organic Methods Evaluation Branch OSHA Analytical Lab- oratory Salt Lake City, Utah, June 1987. Gandelman, M. S. and Birks, J. W., Photore- duction-fluorescence detection of aliphatic alcohols, aldehydes, and ethers in liquid chromatography, Anal. Chem., 54, 2131, 1982. Stibenz, V. D., About the spectralphotometric analysis and the index of purification E235/E280 of glutaraldehyde, Acta Histochem. Bd. , 47, S.83, 1973. Gillett, R. and Gull, K., Glutaraldehyde - its purity and stability, Histochernie, 30, 162, 1972. Hawley, G. G., Freezing point of glutaraldehyde, in The Condensed Chemical Dictionary, 9th ed., Van Nostrand Reinhold, New York, 1977, 416.

234. Treibs, W. and Helbig, R., Synthesis with dicarboxylic acids. XXVI. Dialdehydes from dibromo- dicarboxylic acids by Curtius degradation, Chem. Ber., 92, 1559, 1562, 1959.

235. Brabec, M. J., Aldehydes and acetals, in Patty’s Industrial Hygiene and Toxicology, Vol. 2A, 3rd ed., Clayton, G. D. and Clayton, F. E., Eds., John Wiley & Sons, New York, 1981, 2629.

236. Longley, R. I. and Emerson, W. S., The 1,4-addition of vinyl ethers to alpha,beta-unsaturated car- bony1 compounds, J . Am. Chem. SOC., 72, 3079, 1950.

237. Osol, A. and Hoover, J. E., et al., Eds., Glutar- aldehyde - odor, in Remington’s Pharmaceutical Sciences, 15th ed., Mack Publishing, Easton, PA, 1975, 1103.

238. Vanhaecke, E. , Renders, M., Declercq, B. , Logghe, M., and Puck, J., Evaluation of the stability and sporicidal activity of three glutaraldehyde solutions during hospital continuous use, J . Pharm. Belg., 44, 127, 1989.

239. Sax, N. I. and Lewis, R. J., Eds., Glutaraldehyde, in Dangerous Properties of Industrial Materials, 7th ed., Van Nostrand Reinhold, New York, 1989, 1809.

240. Ohsumi, T. and Kuroki, K., Acute toxicity of glutaraldehyde, Kyushu Shika Gakkai Zasshi, 42, 470, 1988.

241. Hardy, P. M., Nicholls, A. C., and Rydon, H. N., The hydration and polymerisation of succinaldehyde, glutaraldehyde, and adipaldehyde, J . Chem. SOC. Perkin I I , p. 2270, 1972.

173

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

242. Watanabe, Y., Shim, S. C. , Mitsudo, T., Landscheidt, A., and Schlenker, W., Addition of aldehydes to activated double bonds. XIn. Syntheses of tri- and polyketones, C k m . Ber., 110, 1007, 1977.

244. Boswell, G . A., Jr. and Morris, R. C., Polyols from dihydroxy aliphatic aldehydes, U.S. 3,168,579

Yamashita, M., and Takegami, Y., The facile synthesis of N-substituted piperidines from glutaraldehyde and primary mines with tetracarbonylhydrio- ferrate, Bull. Chem. SOC. Jpn., 49, 2302, 1976.

243. Stetter, H., Basse, W., Kuhlmann, H. , (to Shell Oil Co.), February 2, 1965.

1 74

Cri

tical

Rev

iew

s in

Tox

icol

ogy

Dow

nloa

ded

from

info

rmah

ealth

care

.com

by

HIN

AR

I on

04/

08/1

1Fo

r pe

rson

al u

se o

nly.

glutaraldehido 8

Documents

Transcript of glutaraldehido 8